

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549  
**FORM 10-Q**

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**For the quarterly period ended June 1, 2017**  
**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**For the transition period from            to**  
**Commission file number 1-10658**

**Micron Technology, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**75-1618004**  
(IRS Employer Identification No.)

**8000 S. Federal Way, Boise, Idaho**  
(Address of principal executive offices)

**83716-9632**  
(Zip Code)

Registrant's telephone number, including area code

**(208) 368-4000**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer <input checked="" type="radio"/>	Accelerated Filer <input type="radio"/>	Non-Accelerated Filer <input type="radio"/>	Smaller Reporting Company <input type="radio"/>	Emerging Growth Company <input type="radio"/>
(Do not check if a smaller reporting company)				

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The number of outstanding shares of the registrant's common stock as of June 23, 2017, was 1,114,065,834.

---

---

### Definitions of Commonly Used Terms

As used herein, "we," "our," "us," and similar terms include Micron Technology, Inc. and our consolidated subsidiaries, unless the context indicates otherwise. Abbreviations, terms, or acronyms are commonly used or found in multiple locations throughout this report and include the following:

Term	Definition	Term	Definition
2021 MSAC Term Loan	Variable Rate MSAC Senior Secured Term Loan due 2021	Micron	Micron Technology, Inc. (Parent Company)
2021 MSTW Term Loan	Variable Rate MSTW Senior Secured Term Loan due 2021	MMJ	Micron Memory Japan, Inc.
2022 Term Loan B	Senior Secured Term Loan B due 2022	MMJ Companies	MAI and MMJ
2032 Notes	2032C and 2032D Notes	MMJ Group	MMJ and its subsidiaries
2032C Notes	2.375% Convertible Senior Notes due 2032	MMT	Micron Memory Taiwan Co., Ltd.
2032D Notes	3.125% Convertible Senior Notes due 2032	MSTW	Micron Semiconductor Taiwan Co., Ltd.
2033 Notes	2033E and 2033F Notes	MTTW	Micron Technology Taiwan, Inc.
2033E Notes	1.625% Convertible Senior Notes due 2033	Nanya	Nanya Technology Corporation
2033F Notes	2.125% Convertible Senior Notes due 2033	Qimonda	Qimonda AG
2043G Notes	3.00% Convertible Senior Notes due 2043	R&D	Research and Development
Elpida	Elpida Memory, Inc.	SG&A	Selling, General, and Administrative
IMFT	IM Flash Technologies, LLC	SSD	Solid-State Drive
Inotera	Inotera Memories, Inc.	TAIBOR	Taipei Interbank Offered Rate
Intel	Intel Corporation	Tera Probe	Tera Probe, Inc.
Japan Court	Tokyo District Court	VIE	Variable Interest Entity
MAI	Micron Akita, Inc.		

### Additional Information

Ballistix, Crucial, Elpida, JumpDrive, Lexar, Micron, SpecTek, any associated logos, and all other Micron trademarks are the property of Micron. 3D XPoint is a trademark of Intel in the U.S. and/or other countries. Other product names or trademarks that are not owned by Micron are for identification purposes only and may be the registered or unregistered trademarks of their respective owners.

## PART I. FINANCIAL INFORMATION

### ITEM 1. FINANCIAL STATEMENTS

#### MICRON TECHNOLOGY, INC.

#### CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions except per share amounts)

(Unaudited)

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Net sales	\$ 5,566	\$ 2,898	\$ 14,184	\$ 9,182
Cost of goods sold	2,957	2,400	8,860	7,256
Gross margin	2,609	498	5,324	1,926
Selling, general, and administrative	204	148	550	502
Research and development	434	382	1,377	1,206
Restructure and asset impairments	12	—	45	16
Other operating (income) expense, net	(4)	(5)	(14)	2
Operating income (loss)	1,963	(27)	3,366	200
Interest income	10	10	25	33
Interest expense	(153)	(109)	(453)	(302)
Other non-operating income (expense), net	(83)	(34)	(63)	(44)
	1,737	(160)	2,875	(113)
Income tax (provision) benefit	(92)	(15)	(161)	(16)
Equity in net income (loss) of equity method investees	2	(40)	7	24
Net income (loss)	1,647	(215)	2,721	(105)
Net (income) attributable to noncontrolling interests	—	—	—	(1)
Net income (loss) attributable to Micron	\$ 1,647	\$ (215)	\$ 2,721	\$ (106)
Earnings (loss) per share				
Basic	\$ 1.49	\$ (0.21)	\$ 2.52	\$ (0.10)
Diluted	1.40	(0.21)	2.38	(0.10)
Number of shares used in per share calculations				
Basic	1,106	1,036	1,082	1,035
Diluted	1,177	1,036	1,142	1,035

*See accompanying notes to consolidated financial statements.*

**MICRON TECHNOLOGY, INC.**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

(in millions)

(Unaudited)

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Net income (loss)	\$ 1,647	\$ (215)	\$ 2,721	\$ (105)
Other comprehensive income (loss), net of tax				
Foreign currency translation adjustments	11	39	48	(50)
Gain (loss) on derivatives, net	6	3	(1)	2
Pension liability adjustments	1	—	—	(5)
Gain (loss) on investments, net	1	4	—	2
Other comprehensive income (loss)	19	46	47	(51)
Total comprehensive income (loss)	1,666	(169)	2,768	(156)
Comprehensive (income) attributable to noncontrolling interests	—	—	—	(1)
Comprehensive income (loss) attributable to Micron	<u>\$ 1,666</u>	<u>\$ (169)</u>	<u>\$ 2,768</u>	<u>\$ (157)</u>

*See accompanying notes to consolidated financial statements.*

**MICRON TECHNOLOGY, INC.**

**CONSOLIDATED BALANCE SHEETS**

(in millions except par value amounts)

(Unaudited)

As of	June 1, 2017	September 1, 2016
<b>Assets</b>		
Cash and equivalents	\$ 4,048	\$ 4,140
Short-term investments	282	258
Receivables	3,497	2,068
Inventories	3,064	2,889
Other current assets	132	140
Total current assets	11,023	9,495
Long-term marketable investments	471	414
Equity method investments	15	1,364
Deferred tax assets	667	657
Property, plant, and equipment, net	19,014	14,686
Intangible assets, net	405	464
Goodwill	1,228	104
Other noncurrent assets	444	356
Total assets	\$ 33,267	\$ 27,540
<b>Liabilities and equity</b>		
Accounts payable and accrued expenses	\$ 3,656	\$ 3,879
Deferred income	326	200
Current debt	1,161	756
Total current liabilities	5,143	4,835
Long-term debt	10,485	9,154
Other noncurrent liabilities	595	623
Total liabilities	16,223	14,612
<b>Commitments and contingencies</b>		
Redeemable convertible notes	25	—
<b>Micron shareholders' equity</b>		
Common stock, \$0.10 par value, 3,000 shares authorized, 1,114 shares issued and 1,110 outstanding (1,094 issued and 1,040 outstanding as of September 1, 2016)	111	109
Additional capital	8,222	7,736
Retained earnings	7,893	5,299
Treasury stock, 4 shares held (54 as of September 1, 2016)	(67)	(1,029)
Accumulated other comprehensive income (loss)	12	(35)
Total Micron shareholders' equity	16,171	12,080
Noncontrolling interests in subsidiaries	848	848
Total equity	17,019	12,928
Total liabilities and equity	\$ 33,267	\$ 27,540

*See accompanying notes to consolidated financial statements.*

**MICRON TECHNOLOGY, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

(in millions)

(Unaudited)

Nine months ended	June 1, 2017	June 2, 2016
<b>Cash flows from operating activities</b>		
Net income (loss)	\$ 2,721	\$ (105)
Adjustments to reconcile net income (loss) to net cash provided by operating activities		
Depreciation expense and amortization of intangible assets	2,795	2,266
Amortization of debt discount and other costs	93	94
Stock-based compensation	158	148
Loss on restructure of debt	62	4
Gain on remeasurement of previously-held equity interest in Inotera	(71)	—
Equity in net (income) loss of equity method investees	(7)	(24)
Change in operating assets and liabilities		
Receivables	(1,338)	468
Inventories	108	(580)
Accounts payable and accrued expenses	511	3
Payments attributed to intercompany balances with Inotera	(361)	—
Deferred income taxes, net	80	11
Other	199	(13)
Net cash provided by operating activities	4,950	2,272
<b>Cash flows from investing activities</b>		
Expenditures for property, plant, and equipment	(3,469)	(3,894)
Acquisition of Inotera	(2,634)	—
Purchases of available-for-sale securities	(943)	(879)
Payments to settle hedging activities	(267)	(107)
Proceeds from sales and maturities of available-for-sale securities	857	3,189
Proceeds from settlement of hedging activities	146	190
Other	71	(141)
Net cash provided by (used for) investing activities	(6,239)	(1,642)
<b>Cash flows from financing activities</b>		
Proceeds from issuance of debt	3,136	2,166
Proceeds from issuance of stock under equity plans	108	30
Proceeds from equipment sale-leaseback transactions	—	538
Repayments of debt	(1,774)	(689)
Payments on equipment purchase contracts	(261)	(14)
Cash paid to acquire treasury stock	(35)	(147)
Other	33	(181)
Net cash provided by (used for) financing activities	1,207	1,703
Effect of changes in currency exchange rates on cash and equivalents	(10)	7
Net increase (decrease) in cash and equivalents	(92)	2,340
Cash and equivalents at beginning of period	4,140	2,287
Cash and equivalents at end of period	\$ 4,048	\$ 4,627

*See accompanying notes to consolidated financial statements.*

## MICRON TECHNOLOGY, INC.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(All tabular amounts in millions except per share amounts)

(Unaudited)

#### Business and Basis of Presentation

We are a world leader in innovative memory solutions. Through our global brands – Micron®, Crucial®, Lexar®, and Ballistix® – our broad portfolio of high-performance memory technologies, including DRAM, NAND, NOR Flash, and 3D XPoint™ memory, is transforming how the world uses information. Backed by more than 35 years of technology leadership, our memory solutions enable the world's most innovative computing, consumer, enterprise storage, data center, mobile, embedded, and automotive applications. The accompanying consolidated financial statements include the accounts of Micron and our consolidated subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended September 1, 2016. In the opinion of our management, the accompanying unaudited consolidated financial statements contain all necessary adjustments, consisting of a normal recurring nature, to fairly state the financial information set forth herein. Certain reclassifications have been made to prior period amounts to conform to current period presentation.

Our fiscal year is the 52 or 53-week period ending on the Thursday closest to August 31. Fiscal years 2017 and 2016 each contain 52 weeks. All period references are to our fiscal periods unless otherwise indicated. These interim financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended September 1, 2016.

#### Variable Interest Entities

We have interests in entities that are VIEs. If we are the primary beneficiary of a VIE, we are required to consolidate it. To determine if we are the primary beneficiary, we evaluate whether we have the power to direct the activities that most significantly impact the VIE's economic performance and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. Our evaluation includes identification of significant activities and an assessment of our ability to direct those activities based on governance provisions and arrangements to provide or receive product and process technology, product supply, operations services, equity funding, financing, and other applicable agreements and circumstances. Our assessments of whether we are the primary beneficiary of our VIEs require significant assumptions and judgments.

#### Unconsolidated VIEs

**Inotera:** Prior to our acquisition of the remaining interest in Inotera on December 6, 2016, Inotera was a VIE because of the terms of its supply agreement with us. We had determined that we did not have the power to direct the activities of Inotera that most significantly impacted its economic performance, primarily due to limitations on our governance rights that required the consent of other parties for key operating decisions and due to Inotera's dependence on Nanya for financing and the ability of Inotera to operate in Taiwan. Therefore, we did not consolidate Inotera and we accounted for our interest under the equity method. (See "Acquisition of Inotera" and "Equity Method Investments – Inotera" notes.)

**EQUVO:** EQUVO HK Limited ("EQUVO"), a special purpose entity, was created to facilitate an equipment sale-leaseback financing transaction between us and a consortium of financial institutions. Neither we nor the financing entities have an equity interest in EQUVO. EQUVO was a VIE because its equity was not sufficient to permit it to finance its activities without additional support from the financing entities and because the third-party equity holder lacked characteristics of a controlling financial interest. By design, the arrangement with EQUVO was merely a financing vehicle and we did not bear any significant risks from variable interests with EQUVO. Therefore, we had determined that we did not have the power to direct the activities of EQUVO that most significantly impact its economic performance and we did not consolidate EQUVO. In February 2017, we completed all of our obligations under the sale-leaseback financing and no longer have any variable interests in EQUVO.

**SC Hiroshima Energy Corporation:** SC Hiroshima Energy Corporation ("SCHE") is an entity created to construct and operate a cogeneration, electrical power plant to support our wafer manufacturing facility in Hiroshima, Japan. We do not have an equity interest in SCHE. SCHE is a VIE due to the nature of its tolling agreements with us and our option to purchase SCHE's assets. We do not control the operation and maintenance of the plant, which we have determined are the activities of SCHE that most significantly impact its economic performance. Therefore, we do not consolidate SCHE.

**PTI Xi'an:** Powertech Technology Inc. Xi'an ("PTI Xi'an") is a wholly-owned subsidiary of Powertech Technology Inc. ("PTI") and was created to provide assembly services to us at our manufacturing site in Xi'an, China. We do not have an equity interest in PTI Xi'an. PTI Xi'an is a VIE because of the terms of its service agreement with us and its dependency on PTI to finance its operations. We have determined that we do not have the power to direct the activities of PTI Xi'an that most significantly impact its economic performance, primarily because we have no governance rights. Therefore, we do not consolidate PTI Xi'an.

### **Consolidated VIE**

**IMFT:** IMFT is a VIE because all of its costs are passed to us and its other member, Intel, through product purchase agreements and because IMFT is dependent upon us or Intel for additional cash requirements. The primary activities of IMFT are driven by the constant introduction of product and process technology. Because we perform a significant majority of the technology development, we have the power to direct its key activities. In addition, IMFT manufactures certain products exclusively for us using our technology. We consolidate IMFT because we have the power to direct the activities of IMFT that most significantly impact its economic performance and because we have the obligation to absorb losses and the right to receive benefits from IMFT that could potentially be significant to it. (See "Equity – Noncontrolling Interests in Subsidiaries – IMFT" note.)

## **Recently Adopted Accounting Standards**

In January 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-04 – *Simplifying the Test for Goodwill Impairment*, which modified the goodwill impairment test and required an entity to write down the carrying value of goodwill up to the amount by which the carrying amount of a reporting unit exceeded its fair value. We adopted this ASU as of the beginning of the fourth quarter of 2017 in connection with our annual impairment test. The adoption of the ASU itself did not have a material impact on our financial statements.

In March 2016, the FASB issued ASU 2016-09 – *Improvements to Employee Share-Based Payment Accounting*, which simplified several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification within the statement of cash flows. We adopted this ASU as of the beginning of the first quarter of 2017 and elected to account for forfeitures when they occur, on a modified retrospective basis. As a result of the adoption of this ASU, in the first quarter of 2017, we recognized deferred tax assets of \$325 million for the excess tax benefits that arose directly from tax deductions related to equity compensation greater than amounts recognized for financial reporting and also recognized an increase of an equal amount in the valuation allowance against those deferred tax assets. The adoption did not have any other material impacts on our financial statements.

In April 2015, the FASB issued ASU 2015-05 – *Customer's Accounting for Fees Paid in a Cloud Computing Arrangement*, which provided additional guidance to customers about whether a cloud computing arrangement included a software license. Under ASU 2015-05, cloud computing arrangements that contain a software license should be accounted for in a manner consistent with the acquisition of other software licenses, otherwise customers should account for the arrangement as a service contract. ASU 2015-05 also removed the requirement to analogize to ASC 840-10 – *Leases*, to determine the asset acquired in a software licensing arrangement. We adopted this ASU as of the beginning of the first quarter of 2017 on a prospective basis. The adoption of this ASU did not have a material impact on our financial statements.

In February 2015, the FASB issued ASU 2015-02 – *Amendments to the Consolidation Analysis*, which amended the consolidation requirements in Accounting Standards Codification 810 – *Consolidation*. ASU 2015-02 made targeted amendments to the consolidation guidance for VIEs. We adopted this ASU as of the beginning of the first quarter of 2017 under a modified-retrospective approach. The adoption of this ASU did not have an impact on our financial statements.



## Recently Issued Accounting Standards

In November 2016, the FASB issued ASU 2016-18 – *Restricted Cash*, which requires amounts generally described as restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the total beginning and ending amounts for the periods shown on the statement of cash flows. This ASU will be effective for us in the first quarter of 2019 with early adoption permitted and requires retrospective adoption. We are evaluating the timing of our adoption of this ASU on our financial statements.

In October 2016, the FASB issued ASU 2016-16 – *Intra-Entity Transfers Other Than Inventory*, which requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This ASU will be effective for us in the first quarter of 2019 with early adoption permitted and requires modified retrospective adoption. We are evaluating the timing and effects of our adoption of this ASU on our financial statements.

In June 2016, the FASB issued ASU 2016-13 – *Measurement of Credit Losses on Financial Instruments*, which requires a financial asset (or a group of financial assets) measured on the basis of amortized cost to be presented at the net amount expected to be collected. This ASU requires that the income statement reflect the measurement of credit losses for newly recognized financial assets as well as the expected increases or decreases of expected credit losses that have taken place during the period. This ASU requires that credit losses of debt securities designated as available-for-sale be recorded through an allowance for credit losses and limits the credit loss to the amount by which fair value is below amortized cost. This ASU will be effective for us in the first quarter of 2021; however, we are permitted to adopt this ASU as early as the first quarter of 2020. This ASU requires modified retrospective adoption, with prospective adoption for debt securities for which an other-than-temporary impairment had been recognized before the effective date. We are evaluating the timing and effects of our adoption of this ASU on our financial statements.

In February 2016, the FASB issued ASU 2016-02 – *Leases*, which amends a number of aspects of lease accounting, including requiring lessees to recognize operating leases with a term greater than one year on their balance sheet as a right-of-use asset and corresponding liability, measured at the present value of the lease payments. This ASU will be effective for us in the first quarter of 2020 with early adoption permitted and requires modified retrospective adoption. The adoption of this ASU will result in an increase to our consolidated balance sheets for these right-of-use assets and corresponding liabilities. We are evaluating the timing and other effects of our adoption of this ASU on our financial statements.

In January 2016, the FASB issued ASU 2016-01 – *Recognition and Measurement of Financial Assets and Financial Liabilities*, which provides guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. This ASU will be effective for us in the first quarter of 2019 and requires modified retrospective adoption. We are evaluating the effects of our adoption of this ASU on our financial statements.

In May 2014, the FASB issued ASU 2014-09 – *Revenue from Contracts with Customers*, which supersedes nearly all existing revenue recognition guidance under generally accepted accounting principles in the U.S. The core principal of this ASU, as amended, is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. We are required to adopt this ASU in the first quarter of 2019; however, we are permitted to adopt this ASU as early as the first quarter of 2018. This ASU allows for either full retrospective or modified retrospective adoption. We expect that, as a result of the adoption of this ASU, the timing of recognizing revenue from sales of products to our distributors under agreements allowing rights of return or price protection will be generally earlier than under the existing revenue recognition guidance. After adoption, the impact of this change in any reporting period would be the net effect of changes to revenue recognized as of the beginning and end of each period. Revenue recognized upon resale by our customers with these rights was 19% and 21% of total sales for the third quarter and first nine months of 2017, respectively, and 26% and 24% for the third quarter and first nine months of 2016, respectively. We are evaluating the timing, method, and other effects of our adoption of this ASU on our financial statements.

## Acquisition of Inotera

Through December 6, 2016, we held a 33% ownership interest in Inotera, now known as Micron Technology Taiwan, Inc. ("MTTW"), Nanya and certain of its affiliates held a 32% ownership interest, and the remaining ownership interest was publicly held. On December 6, 2016, we acquired the 67% remaining interest in Inotera not owned by us (the "Inotera Acquisition") and began consolidating Inotera's operating results. The cash paid for the Inotera Acquisition was funded, in part, with proceeds from the 2021 MSTW Term Loan and the sale of the Micron Shares (as defined below) to Nanya. Inotera manufactures DRAM products at its 300mm wafer fabrication facility in Taoyuan City, Taiwan, and sold such products exclusively to us through supply agreements. SG&A expenses for the first six months of 2017 and for full fiscal 2016 included transaction costs of \$13 million and \$3 million, respectively, incurred in connection with the Inotera Acquisition.

In connection with the Inotera Acquisition, we revalued our previously-held 33% equity interest to its fair value. In determining the fair value, we used various valuation techniques, including the share price of Inotera prior to the announcement of the Inotera Acquisition and discounted cash flow projections using inputs including discount rate and terminal growth rate (Level 3). As a result, we recognized a non-operating gain of \$71 million in the second quarter of 2017.

In connection with the Inotera Acquisition, we sold 58 million shares of our common stock to Nanya (the "Micron Shares") and received cash proceeds of \$986 million. Because the sale of the Micron Shares to Nanya was contemporaneous with, and contingent upon, the closing the Inotera Acquisition, the issuance of the Micron Shares was treated in purchase accounting as a non-cash exchange for a portion of the shares of Inotera held by Nanya. The Micron Shares were issued in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended, and subject to certain restrictions on transfers. To reflect the lack of transferability, the fair value of the Micron Shares (based on the trading price of our common stock on the acquisition date) was reduced by a discount of \$81 million, based on the implied volatility derived from traded options on our stock and on the duration of the lack of transferability (Level 2).

We provisionally estimated the fair value of the Inotera assets acquired and liabilities assumed as of the December 6, 2016 acquisition date. In the third quarter of 2017, we incorporated additional information in our analysis about facts and circumstances that existed as of the acquisition date and adjusted our provisional values, which resulted in a decrease in the amount of purchase price allocated to property, plant, and equipment of \$59 million and increases in the amounts allocated to other noncurrent assets of \$13 million, deferred income taxes of \$8 million, and goodwill of \$38 million. The allocation of purchase price to assets acquired and liabilities assumed of Inotera could further change as additional information becomes available. The consideration and provisional valuation of assets acquired and liabilities assumed, as adjusted in the third quarter of 2017, are as follows:

#### Consideration

Cash paid for Inotera Acquisition	\$	4,099
Less cash received from selling Micron Shares		(986)
Net cash paid for Inotera Acquisition		3,113
Fair value of our previously-held equity interest in Inotera		1,441
Fair value of Micron Shares exchanged for Inotera shares		995
Other		3
Payments attributed to intercompany balances with Inotera		(361)
	\$	5,191

#### Assets acquired and liabilities assumed

Cash and equivalents	\$	118
Inventories		285
Other current assets		27
Property, plant, and equipment		3,722
Deferred tax assets		82
Goodwill		1,124
Other noncurrent assets		130
Accounts payable and accrued expenses		(232)
Debt		(56)
Other noncurrent liabilities		(9)
	\$	5,191

As a result of the Inotera Acquisition, we expect to experience greater operational flexibility to drive new technology in products manufactured by Inotera, optimize the deployment of our cash flows across our operations, and enhance our ability to adapt our product offerings to changes in market conditions. As a result of these synergies, we allocated goodwill of \$829 million, \$198 million, and \$97 million to CNBU, MBU, and EBU, respectively. Goodwill resulting from the Inotera Acquisition is not deductible for Taiwan corporate income tax purposes; however, it is deductible for Taiwan surtax purposes.

**Unaudited Pro Forma Financial Information**

The following unaudited pro forma financial information presents the combined results of operations as if the Inotera Acquisition had occurred on September 4, 2015. The pro forma financial information includes the accounting effects of the business combination, including adjustments for depreciation of property, plant, and equipment, interest expense, elimination of intercompany activities, and revaluation of inventories. The unaudited pro forma financial information below is not necessarily indicative of either future results of operations or results that might have been achieved had the Inotera Acquisition occurred on September 4, 2015.

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Net sales	\$ 5,566	\$ 2,869	\$ 14,179	\$ 9,141
Net income (loss)	1,696	(303)	2,776	(351)
Net income (loss) attributable to Micron	1,696	(303)	2,776	(352)
Earnings (loss) per share				
Basic	1.53	(0.28)	2.52	(0.32)
Diluted	1.44	(0.28)	2.39	(0.32)

The unaudited pro forma financial information for 2017 includes our results for the quarter and nine months ended June 1, 2017 (which includes the results of Inotera since our acquisition of Inotera on December 6, 2016), the results of Inotera for the three months ended November 30, 2016, and the adjustments described above. The pro forma information for 2016 includes our results for the quarter and nine months ended June 2, 2016, the results of Inotera for the quarter and nine months ended May 31, 2016, and the adjustments described above.

**Technology Transfer and License Agreements with Nanya**

Effective December 6, 2016, under the terms of technology transfer and license agreements, Nanya has options to require us to transfer to Nanya for Nanya's use certain technology and deliverables related to the next DRAM process node generation after our 20nm process node (the "1X Process Node") and the next DRAM process node generation after the 1X Process Node. Under the terms of the agreements, Nanya would pay royalties to us for a license to the transferred technologies based on revenues from products utilizing the technologies, subject to specified caps, and we would also receive an equity interest in Nanya upon the achievement of certain milestones.

## Cash and Investments

Cash and equivalents and the fair values of our available-for-sale investments, which approximated amortized costs, were as follows:

As of	June 1, 2017				September 1, 2016			
	Cash and Equivalents	Short-term Investments	Long-term Marketable Investments <sup>(1)</sup>	Total Fair Value	Cash and Equivalents	Short-term Investments	Long-term Marketable Investments <sup>(1)</sup>	Total Fair Value
Cash	\$ 2,110	\$ —	\$ —	\$ 2,110	\$ 2,258	\$ —	\$ —	\$ 2,258
Level 1 <sup>(2)</sup>								
Money market funds	1,528	—	—	1,528	1,507	—	—	1,507
Level 2 <sup>(3)</sup>								
Corporate bonds	—	172	256	428	—	142	235	377
Certificates of deposit	380	9	8	397	373	33	—	406
Government securities	6	61	76	143	2	62	82	146
Asset-backed securities	—	4	131	135	—	12	97	109
Commercial paper	24	36	—	60	—	9	—	9
	<u>\$ 4,048</u>	<u>\$ 282</u>	<u>\$ 471</u>	<u>\$ 4,801</u>	<u>\$ 4,140</u>	<u>\$ 258</u>	<u>\$ 414</u>	<u>\$ 4,812</u>

<sup>(1)</sup> The maturities of long-term marketable investments range from one to four years.

<sup>(2)</sup> The fair value of Level 1 securities is measured based on quoted prices in active markets for identical assets.

<sup>(3)</sup> The fair value of Level 2 securities is measured using information obtained from pricing services, which obtain quoted market prices for similar instruments, non-binding market consensus prices that are corroborated by observable market data, or various other methodologies, to determine the appropriate value at the measurement date. We perform supplemental analysis to validate information obtained from these pricing services. No adjustments were made to such pricing information as of June 1, 2017.

Proceeds from sales of available-for-sale securities were \$194 million and \$742 million for the third quarter and first nine months of 2017, respectively, and \$902 million and \$1.89 billion for the third quarter and first nine months of 2016, respectively. Gross realized gains and losses from sales of available-for-sale securities were not material for any period presented. As of June 1, 2017, there were no available-for-sale securities that had been in a loss position for longer than 12 months.

Restricted cash, included in other noncurrent assets and excluded from the table above, was \$98 million and \$122 million as of June 1, 2017 and September 1, 2016, respectively.

## Receivables

As of	June 1, 2017	September 1, 2016
Trade receivables	\$ 3,188	\$ 1,765
Income and other taxes	90	119
Other	219	184
	<u>\$ 3,497</u>	<u>\$ 2,068</u>

## Inventories

As of	June 1, 2017	September 1, 2016
Finished goods	\$ 857	\$ 899
Work in process	1,901	1,761
Raw materials and supplies	306	229
	<u>\$ 3,064</u>	<u>\$ 2,889</u>

## Property, Plant, and Equipment

As of	September 1, 2016	Additions	Retirements and Other	June 1, 2017
Land	\$ 145	\$ 205	\$ (5)	\$ 345
Buildings	6,653	946	(30)	7,569
Equipment <sup>(1)</sup>	25,910	5,934	(495)	31,349
Construction in progress <sup>(2)</sup>	475	56	33	564
Software	422	21	(1)	442
	33,605	7,162	(498)	40,269
Accumulated depreciation	(18,919)	(2,714)	378	(21,255)
	<u>\$ 14,686</u>	<u>\$ 4,448</u>	<u>\$ (120)</u>	<u>\$ 19,014</u>

<sup>(1)</sup> Included costs related to equipment not placed into service of \$731 million and \$1.47 billion as of June 1, 2017 and September 1, 2016, respectively.

<sup>(2)</sup> Included building-related construction and tool installation costs for assets not placed into service.

Depreciation expense was \$994 million and \$2.71 billion for the third quarter and first nine months of 2017, respectively, and \$725 million and \$2.18 billion for the third quarter and first nine months of 2016, respectively. In the fourth quarter of 2016, we revised the estimated useful lives of equipment in our DRAM wafer fabrication facilities from five to seven years, which reduced depreciation costs by approximately \$100 million per quarter in 2017.

## Equity Method Investments

As of	June 1, 2017		September 1, 2016	
	Investment Balance	Ownership Percentage	Investment Balance	Ownership Percentage
Inotera	\$ —	—%	\$ 1,314	33%
Tera Probe	—	—%	36	40%
Other	15	Various	14	Various
	<u>\$ 15</u>		<u>\$ 1,364</u>	

Equity in net income (loss) of equity method investees, net of tax, included the following:

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Inotera	\$ —	\$ (19)	\$ 9	\$ 35
Tera Probe	2	(22)	(3)	(16)
Other	—	1	1	5
	<u>\$ 2</u>	<u>\$ (40)</u>	<u>\$ 7</u>	<u>\$ 24</u>

### Inotera

We held a 33% interest in Inotera, a Taiwan DRAM memory company, through December 6, 2016, at which time we acquired the remaining 67% interest in Inotera. Historically, we accounted for our interest in Inotera on a two-month lag under the equity method. As a result of the Inotera Acquisition, we account for Inotera without a lag, consistent with our other wholly-owned subsidiaries.

From January 2013 through December 2015, we purchased all of Inotera's DRAM output under supply agreements at prices reflecting discounts from market prices for our comparable components. After December 2015 and until our acquisition of the remaining interest in Inotera, the price for DRAM products purchased by us was based on a formula that equally shared margin between Inotera and us. We purchased \$504 million of DRAM products from Inotera in the first quarter of 2017 and \$348 million and \$1.05 billion in the third quarter and first nine months of 2016, respectively.

### Tera Probe

In the third quarter of 2017, we sold our 40% interest in Tera Probe, which provides semiconductor wafer testing and probe services to us and others, in a transaction that included the pending sale of our assembly and test facility located in Akita, Japan. (See "Restructure and Asset Impairments" note.) In the first quarter of 2017 and third quarter of 2016, we recorded impairment charges of \$16 million and \$25 million, respectively, within equity in net income (loss) of equity method investees to write down the carrying value of our investment in Tera Probe to its then fair value based on its trading price (Level 1). We incurred manufacturing costs for services performed by Tera Probe of \$15 million and \$47 million in the third quarter and first nine months of 2017, respectively, and \$19 million and \$58 million in the third quarter and first nine months of 2016, respectively.

## Intangible Assets and Goodwill

As of	June 1, 2017		September 1, 2016	
	Gross Amount	Accumulated Amortization	Gross Amount	Accumulated Amortization
Amortizing assets				
Product and process technology	\$ 756	\$ (459)	\$ 757	\$ (402)
Other	1	(1)	1	—
	<u>757</u>	<u>(460)</u>	<u>758</u>	<u>(402)</u>
Non-amortizing assets				
In-process R&D	108	—	108	—
	<u>108</u>	<u>—</u>	<u>108</u>	<u>—</u>
Total intangible assets	<u>\$ 865</u>	<u>\$ (460)</u>	<u>\$ 866</u>	<u>\$ (402)</u>
Goodwill	<u>\$ 1,228</u>		<u>\$ 104</u>	

During the first nine months of 2017 and 2016, we capitalized \$22 million and \$24 million, respectively, for product and process technology with weighted-average useful lives of 10 years. Amortization expense was \$27 million and \$81 million for the third quarter and first nine months of 2017, respectively, and \$30 million and \$90 million for the third quarter and first nine months of 2016, respectively. Expected amortization expense is \$28 million for the remainder of 2017, \$97 million for 2018, \$48 million for 2019, \$31 million for 2020, and \$26 million for 2021.

## Accounts Payable and Accrued Expenses

As of	June 1, 2017	September 1, 2016
Accounts payable	\$ 1,494	\$ 1,186
Property, plant, and equipment payables	1,096	1,649
Salaries, wages, and benefits	505	289
Customer advances	156	132
Income and other taxes	104	41
Related party payables	—	273
Other	301	309
	<u>\$ 3,656</u>	<u>\$ 3,879</u>

As of September 1, 2016, related party payables included \$266 million due to Inotera primarily for the purchase of DRAM products.



## Debt

As of	June 1, 2017					September 1, 2016		
	Stated Rate	Effective Rate	Current	Long-Term	Total	Current	Long-Term	Total
MMJ creditor installment payments	N/A	6.52%	\$ 154	\$ 465	\$ 619	\$ 189	\$ 680	\$ 869
Capital lease obligations	N/A	3.64%	355	917	1,272	380	1,026	1,406
2021 MSAC senior secured term loan	3.467%	3.76%	38	583	621	—	—	—
2021 MSTW senior secured term loan	2.852%	3.02%	—	2,643	2,643	—	—	—
2022 senior notes	5.875%	6.14%	—	591	591	—	590	590
2022 senior secured term loan B	3.550%	3.97%	5	726	731	5	730	735
2023 senior notes	5.250%	5.43%	—	991	991	—	990	990
2023 senior secured notes	7.500%	7.69%	—	1,238	1,238	—	1,237	1,237
2024 senior notes	5.250%	5.38%	—	546	546	—	546	546
2025 senior notes	5.500%	5.56%	—	515	515	—	1,139	1,139
2026 senior notes	5.625%	5.73%	—	128	128	—	446	446
2032C convertible senior notes <sup>(1)</sup>	2.375%	5.95%	—	209	209	—	204	204
2032D convertible senior notes <sup>(1)</sup>	3.125%	6.33%	—	157	157	—	154	154
2033E convertible senior notes <sup>(1)</sup>	1.625%	4.50%	169	—	169	—	168	168
2033F convertible senior notes <sup>(1)</sup>	2.125%	4.93%	276	—	276	—	271	271
2043G convertible senior notes	3.000%	6.76%	—	668	668	—	657	657
Other notes payable	2.038%	2.57%	164	108	272	182	316	498
			<u>\$ 1,161</u>	<u>\$ 10,485</u>	<u>\$ 11,646</u>	<u>\$ 756</u>	<u>\$ 9,154</u>	<u>\$ 9,910</u>

<sup>(1)</sup> Since the closing price of our common stock exceeded 130% of the conversion price per share for at least 20 trading days in the 30 trading day period ended on March 31, 2017, these notes are convertible by the holders through the calendar quarter ending June 30, 2017. The closing price of our common stock also exceeded the thresholds for the calendar quarter ended June 30, 2017; therefore, these notes are convertible by the holders through September 30, 2017. The 2033 Notes were classified as current as of June 1, 2017 because the terms of these notes require us to pay cash for the principal amount of any converted notes and holders of these notes had the right to convert their notes as of that date. In addition, the holders of the 2033E Notes can require us to repurchase for cash all or a portion of the 2033E Notes on February 15, 2018.

### Debt Restructure

On April 11, 2017, we repurchased \$631 million of principal amount of our 2025 Notes (carrying value of \$625 million) and \$321 million of principal amount of our 2026 Notes (carrying value of \$318 million) for an aggregate of \$1.00 billion in cash. In connection with the transactions, we recognized a non-operating loss of \$60 million in the third quarter of 2017.

### Capital Lease Obligations

In the third quarter of 2017, we recorded capital lease obligations aggregating \$84 million at a weighted-average effective interest rate of 6.5% and a weighted-average expected term of 5 years. In the first nine months of 2017, we recorded capital lease obligations aggregating \$217 million.

### **2021 MSAC Senior Secured Term Loan**

In November 2016, we entered into a five-year variable-rate facility agreement to obtain up to \$800 million of financing, collateralized by certain production equipment. On March 6, 2017 and December 2, 2016, we drew \$175 million and \$450 million, respectively, under the 2021 MSAC Term Loan. On June 5, 2017, subsequent to the end of our third quarter of 2017, we drew the remaining \$175 million under this facility. Interest is payable quarterly at a per annum rate equal to three-month LIBOR plus 2.4%. Principal is payable in 16 equal quarterly installments beginning in March 2018. The 2021 MSAC Term Loan contains covenants which are customary for financings of this type, including negative covenants that limit or restrict our ability to create liens or dispose of the equipment securing the facility agreement. The 2021 MSAC Term Loan also contains a covenant that the ratio of the outstanding loan to the fair value of the equipment collateralizing the loan not exceed 0.8. If such ratio is exceeded, we are required to grant a security interest in additional equipment and/or prepay the 2021 MSAC Term Loan in an amount sufficient to reduce such ratio to 0.8 or less. The 2021 MSAC Term Loan also contains customary events of default which could result in the acceleration of all amounts to be immediately due and payable. The 2021 MSAC Term Loan is guaranteed by Micron.

### **2021 MSTW Senior Secured Term Loan**

In connection with the Inotera Acquisition, on December 6, 2016, we drew 80 billion New Taiwan dollars under a collateralized, five-year term loan that bears interest at a variable per annum rate equal to the three-month or six-month TAIBOR, at our option, plus a margin of 2.05%. Principal under the 2021 MSTW Term Loan is payable in six equal semi-annual installments, commencing in June 2019, through December 2021. The 2021 MSTW Term Loan is collateralized by certain assets, including a real estate mortgage on MTTW's main production facility and site, a chattel mortgage over certain equipment of MTTW, all of the stock of our MSTW subsidiary, and the 82% of stock of MTTW owned by MSTW. The 2021 MSTW Term Loan is guaranteed by Micron.

The 2021 MSTW Term Loan contains affirmative and negative covenants, including covenants that limit or restrict our ability to create liens in or dispose of collateral securing obligations under the 2021 MSTW Term Loan, mergers involving MSTW and/or MTTW, loans or guarantees to third parties by MTTW and/or MSTW, and MSTW's and/or MTTW's distribution of cash dividends. The 2021 MSTW Term Loan also contains financial covenants, which are tested semi-annually, as follows:

- MSTW must maintain a consolidated ratio of total liabilities to adjusted EBITDA not higher than 5.5x in 2017 and 2018, and not higher than 4.5x in 2019 through 2021;
- MSTW must maintain adjusted consolidated tangible net worth of not less than 4.0 billion New Taiwan dollars in 2017 and 2018, not less than 6.5 billion New Taiwan dollars in 2019 and 2020, and not less than 12.0 billion New Taiwan dollars in 2021;
- on a consolidated basis, Micron must maintain a ratio of total liabilities to adjusted EBITDA not higher than 3.5x in 2017, not higher than 3.0x in 2018 and 2019, and not higher than 2.5x in 2020 and 2021; and
- on a consolidated basis, Micron must maintain adjusted tangible net worth not less than \$9.0 billion in 2017, not less than \$12.5 billion in 2018 and 2019, and not less than \$16.5 billion in 2020 and 2021.

If MSTW fails to maintain a required financial covenant, the interest rate will be increased by 0.25% until such time as the required financial ratios are maintained. If MSTW's failure continues for two consecutive semi-annual periods, such failure will constitute an event of default that could result in all obligations owed under the 2021 MSTW Term Loan being accelerated to be immediately due and payable. Micron's failure to maintain a required financial covenant will only result in a 0.25% increase to the interest rate but will not constitute an event of default. The 2021 MSTW Term Loan also contains customary events of default.

### **Convertible Senior Notes**

As of June 1, 2017, the trading price of our common stock was higher than the initial conversion prices of our convertible notes. As a result, the conversion values for these notes exceeded the principal amounts by \$1.77 billion as of June 1, 2017.

### **2022 Senior Secured Term Loan B Repricing Amendment**

On April 26, 2017, we amended our 2022 Term Loan B, substantially all of which was treated as a debt modification, to reduce the margins added to the base rate from 2.75% to 1.5% and to the adjusted LIBOR rate from 3.75% to 2.5%. In October 2016, we amended our 2022 Term Loan B, substantially all of which was treated as a debt modification, to reduce the margins added to the base rate from 5.00% to 2.75% and to the adjusted LIBOR rate from 6.00% to 3.75%.

## Contingencies

We have accrued a liability and charged operations for the estimated costs of adjudication or settlement of various asserted and unasserted claims existing as of the balance sheet date, including those described below. We are currently a party to other legal actions arising from the normal course of business, none of which is expected to have a material adverse effect on our business, results of operations, or financial condition.

### Patent Matters

As is typical in the semiconductor and other high-tech industries, from time to time others have asserted, and may in the future assert, that our products or manufacturing processes infringe their intellectual property rights.

On November 21, 2014, Elm 3DS Innovations, LLC ("Elm") filed a patent infringement action against Micron, MSP, and Micron Consumer Products Group, Inc. in the U.S. District Court for the District of Delaware. On March 27, 2015, Elm filed an amended complaint against the same entities. The amended complaint alleges that unspecified semiconductor products of ours that incorporate multiple stacked die infringe thirteen U.S. patents and seeks damages, attorneys' fees, and costs.

On December 15, 2014, Innovative Memory Solutions, Inc. filed a patent infringement action against Micron in the U.S. District Court for the District of Delaware. The complaint alleges that a variety of our NAND products infringe eight U.S. patents and seeks damages, attorneys' fees, and costs.

On June 24, 2016, the President and Fellows of Harvard University filed a patent infringement action against Micron in the U.S. District Court for the District of Massachusetts. The complaint alleges that a variety of our DRAM products infringe two U.S. patents and seeks damages, injunctive relief, and other unspecified relief.

Among other things, the above lawsuits pertain to certain of our DDR DRAM, DDR2 DRAM, DDR3 DRAM, DDR4 DRAM, SDR SDRAM, PSRAM, RDRAM, LPDRAM, NAND, and certain other memory products we manufacture, which account for a significant portion of our net sales.

We are unable to predict the outcome of assertions of infringement made against us and therefore cannot estimate the range of possible loss. A determination that our products or manufacturing processes infringe the intellectual property rights of others or entering into a license agreement covering such intellectual property could result in significant liability and/or require us to make material changes to our products and/or manufacturing processes. Any of the foregoing could have a material adverse effect on our business, results of operations, or financial condition.

### Qimonda

On January 20, 2011, Dr. Michael Jaffé, administrator for Qimonda insolvency proceedings, filed suit against Micron and Micron Semiconductor B.V., our Netherlands subsidiary ("Micron B.V."), in the District Court of Munich, Civil Chamber. The complaint seeks to void under Section 133 of the German Insolvency Act a share purchase agreement between Micron B.V. and Qimonda signed in fall 2008 pursuant to which Micron B.V. purchased substantially all of Qimonda's shares of Inotera (the "Inotera Shares"), representing approximately 18% of Inotera's outstanding shares as of June 1, 2017 and seeks an order requiring us to re-transfer those shares to the Qimonda estate. The complaint also seeks, among other things, to recover damages for the alleged value of the joint venture relationship with Inotera and to terminate under Sections 103 or 133 of the German Insolvency Code a patent cross-license between us and Qimonda entered into at the same time as the share purchase agreement.

Following a series of hearings with pleadings, arguments, and witnesses on behalf of the Qimonda estate, on March 13, 2014, the Court issued judgments: (1) ordering Micron B.V. to pay approximately \$1 million in respect of certain Inotera shares sold in connection with the original share purchase; (2) ordering Micron B.V. to disclose certain information with respect to any Inotera Shares sold by it to third parties; (3) ordering Micron B.V. to disclose the benefits derived by it from ownership of the Inotera Shares, including in particular, any profits distributed on such shares and all other benefits; (4) denying Qimonda's claims against Micron for any damages relating to the joint venture relationship with Inotera; and (5) determining that Qimonda's obligations under the patent cross-license agreement are canceled. In addition, the Court issued interlocutory judgments ordering, among other things: (1) that Micron B.V. transfer to the Qimonda estate the Inotera Shares still owned by it and pay to the Qimonda estate compensation in an amount to be specified for any Inotera Shares sold to third parties; and (2) that Micron B.V. pay the Qimonda estate as compensation an amount to be specified for benefits derived by it from ownership of the Inotera Shares. The interlocutory judgments have no immediate, enforceable effect on us, and, accordingly, we expect to be able to continue to operate with full control of the Inotera Shares subject to further developments in the case. We have filed a notice of appeal, and the parties have submitted briefs to the appeals court.

We are unable to predict the outcome of the matter and therefore cannot estimate the range of possible loss. The final resolution of this lawsuit could result in the loss of the Inotera Shares or monetary damages, unspecified damages based on the benefits derived by Micron B.V. from the ownership of the Inotera Shares, and/or the termination of the patent cross-license, which could have a material adverse effect on our business, results of operation, or financial condition.

## **Other**

In the normal course of business, we are a party to a variety of agreements pursuant to which we may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. Historically, our payments under these types of agreements have not had a material adverse effect on our business, results of operations, or financial condition.

## **Redeemable Convertible Notes**

Under the terms of the indentures governing the 2033 Notes, upon conversion, we would be required to pay cash equal to the lesser of (1) the aggregate principal amount or (2) the conversion value of the notes being converted. To the extent the conversion value exceeds the principal amount, we could pay cash, shares of common stock, or a combination thereof, at our option, for the amount of such excess. The closing price of our common stock met the thresholds for conversion for the calendar quarter ended March 31, 2017; therefore, the 2033 Notes were convertible by the holders as of June 1, 2017. As a result, the 2033 Notes were classified as current debt and the aggregate difference between the principal amount and the carrying value of \$25 million was classified as redeemable convertible notes in the accompanying consolidated balance sheet as of June 1, 2017. The closing price of our common stock did not meet the thresholds for the calendar quarter ended June 30, 2016; therefore, the 2033 Notes were not convertible by the holders as of September 1, 2016. Therefore, as of September 1, 2016, the 2033 Notes had been classified as noncurrent debt and the aggregate difference between the principal amount and the carrying value had been classified as additional capital.

## **Equity**

### **Micron Shareholders' Equity**

**Treasury Stock:** In connection with the Inotera Acquisition, in the second quarter of 2017, we sold 58 million shares of our common stock to Nanya for \$986 million in cash, of which 54 million shares were issued from treasury stock. As a result, in the second quarter of 2017, treasury stock decreased by \$1.03 billion, while retained earnings decreased by \$104 million for the difference between the carrying value of the treasury stock and its \$925 million fair value.

**Outstanding Capped Calls:** Our capped calls are intended to reduce the effect of potential dilution from our convertible notes and provide for our receipt of cash or shares, at our election, from our counterparties if the trading price of our stock is above strike prices on the expiration dates. As of June 1, 2017, the dollar value of cash or shares that we would receive from our outstanding capped calls upon their expiration dates range from \$0, if the trading price of our stock is below strike prices for all capped calls at expiration, to \$527 million, if the trading price of our stock is at or above the cap prices for all capped calls.

**Expiration of Capped Calls:** In the third quarter of 2017, we cash-settled a portion of our 2032C and 2032D Capped Calls and received \$125 million, based on the volume-weighted trading stock prices at the expiration dates. In the second quarter of 2017, we share-settled a portion of our 2032C and 2032D Capped Calls and received 4 million shares of our stock, equal to a value of \$67 million, based on the volume-weighted trading stock prices at the expiration dates. The shares received were recorded as treasury stock.

**Shareholder Rights Agreement:** On January 18, 2017, our shareholders approved a Section 382 Rights Agreement (the "Rights Agreement"), under which our shareholders of record as of the close of business on August 1, 2016 received one right for each share of common stock outstanding, which entitles shareholders to purchase additional shares of our common stock at a significant discount in the event of an ownership change. The Rights Agreement is intended to avoid an ownership change, as defined by Section 382 of the Internal Revenue Code of 1986, as amended, and thereby preserve our current ability to utilize certain net operating loss and credit carryforwards.

#### **Noncontrolling Interests in Subsidiaries**

As of	June 1, 2017		September 1, 2016	
	Noncontrolling Interest Balance	Noncontrolling Interest Percentage	Noncontrolling Interest Balance	Noncontrolling Interest Percentage
IMFT	\$ 832	49%	\$ 832	49%
Other	16	Various	16	Various
	<u>\$ 848</u>		<u>\$ 848</u>	

**IMFT:** Since IMFT's inception in 2006, we have owned 51% of IMFT, a joint venture between us and Intel that manufactures NAND and 3D XPoint memory products exclusively for the members. The members share the output of IMFT generally in proportion to their investment. IMFT is governed by a Board of Managers for which the number of managers appointed by each member varies based on the members' respective ownership interests. The IMFT joint venture agreement extends through 2024 and includes certain buy-sell rights. Through December 2018, Intel can put to us, and from January 2019 through December 2021, we can call from Intel, Intel's interest in IMFT, in either case, for an amount equal to the noncontrolling interest balance attributable to Intel at such time either member exercises its right. If Intel exercises its put right, we can elect to set the closing date of the transaction to be any time within two years following such election by Intel and can elect to receive financing of the purchase price from Intel for one to two years from the closing date. Creditors of IMFT have recourse only to IMFT's assets and do not have recourse to any other of our assets. In the third quarter of 2016, IMFT distributed \$36 million and \$34 million of cash to us and Intel, respectively, and in first nine months of 2016, we and Intel contributed \$38 million and \$37 million, respectively, to IMFT.

IMFT manufactures memory products using designs and technology we develop with Intel. We generally share with Intel the costs of product design and process development activities for NAND and 3D XPoint memory at IMFT and our other facilities. Our R&D expenses were reduced by reimbursements from Intel of \$47 million and \$162 million for the third quarter and first nine months of 2017, respectively, and \$54 million and \$153 million for the third quarter and first nine months of 2016, respectively.

Non-Trade sales primarily consists of NAND and 3D XPoint products manufactured and sold to Intel through IMFT at long-term negotiated prices approximating cost and were \$138 million and \$419 million for the third quarter and first nine months of 2017, respectively, and \$120 million and \$372 million for the third quarter and first nine months of 2016, respectively.

The following table presents the assets and liabilities of IMFT included in our consolidated balance sheets:

As of	June 1, 2017	September 1, 2016
<b>Assets</b>		
Cash and equivalents	\$ 113	\$ 98
Receivables	84	89
Inventories	120	68
Other current assets	4	6
Total current assets	321	261
Property, plant, and equipment, net	1,748	1,792
Other noncurrent assets	49	50
Total assets	\$ 2,118	\$ 2,103
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$ 215	\$ 175
Deferred income	6	7
Current debt	19	16
Total current liabilities	240	198
Long-term debt	80	66
Other noncurrent liabilities	89	94
Total liabilities	\$ 409	\$ 358

Amounts exclude intercompany balances that were eliminated in our consolidated balance sheets.

#### **Restrictions on Net Assets**

As a result of the corporate reorganization proceedings the MMJ Companies initiated in March 2012, and for so long as such proceedings continue, the MMJ Group is subject to certain restrictions on dividends, loans, and advances. In addition, the 2021 MSTW Term Loan contains covenants that limit or restrict the ability of MSTW and/or MTTW to distribute cash dividends. Also, our ability to access the cash and other assets of IMFT through dividends, loans, or advances, including to finance our other operations, is limited and is subject to agreement by Intel. As a result, our total restricted net assets (excluding intercompany balances and noncontrolling interests) as of June 1, 2017 were \$3.48 billion for the MMJ Group, \$2.55 billion for MSTW and MTTW, and \$877 million for IMFT. As of June 1, 2017, the MMJ Group held cash and equivalents of \$595 million, MSTW and MTTW held \$261 million, and IMFT held \$113 million.

#### **Fair Value Measurements**

All of our marketable debt and equity investments (excluding equity method investments) were classified as available-for-sale and carried at fair value. Amounts reported as cash and equivalents, receivables, and accounts payable and accrued expenses approximate fair value. The estimated fair value and carrying value of debt instruments (excluding the carrying value of the equity and mezzanine equity components of our convertible notes) were as follows:

As of	June 1, 2017		September 1, 2016	
	Fair Value	Carrying Value	Fair Value	Carrying Value
Notes and MMJ creditor installment payments	\$ 9,307	\$ 8,895	\$ 7,257	\$ 7,050
Convertible notes	3,747	1,479	2,408	1,454

The fair values of our convertible notes were determined based on inputs that were observable in the market or that could be derived from, or corroborated with, observable market data, including the trading price of our convertible notes when available, our stock price, and interest rates based on similar debt issued by parties with credit ratings similar to ours (Level 2). The fair values of our other debt instruments were estimated based on discounted cash flows using inputs that were observable in the market or that could be derived from, or corroborated with, observable market data, including the trading price of our notes, when available, and interest rates based on similar debt issued by parties with credit ratings similar to ours (Level 2).

## Derivative Instruments

We use derivative instruments to manage our exposure to changes in currency exchange rates from our monetary assets and liabilities denominated in currencies other than the U.S. dollar. We do not use derivative instruments for speculative purpose.

### Derivative Instruments without Hedge Accounting Designation

**Currency Derivatives:** To hedge our exposures of monetary assets and liabilities to changes in currency exchange rates, we generally utilize a rolling hedge strategy with currency forward contracts that mature within nine months. In addition, to mitigate the risk of the yen strengthening against the U.S. dollar on our MMJ creditor installment payments due in December 2017 and 2018, we entered into forward contracts to purchase 18 billion yen in December 2017 and 28 billion yen in December 2018. At the end of each reporting period, monetary assets and liabilities denominated in currencies other than the U.S. dollar are remeasured into U.S. dollars and the associated outstanding forward contracts are marked to market. Currency forward contracts are valued at fair values based on the middle of bid and ask prices of dealers or exchange quotations (Level 2). Total notional amounts and gross fair values for derivative instruments without hedge accounting designation were as follows:

	Notional Amount (in U.S. Dollars)	Fair Value		
		Current Assets <sup>(1)</sup>	Current Liabilities <sup>(2)</sup>	
As of June 1, 2017				
New Taiwan dollar	\$ 3,083	\$ 49	\$ —	
Yen	1,177	4	(1)	
Singapore dollar	389	1	—	
Euro	193	1	—	
Other	45	—	—	
	<u>\$ 4,887</u>	<u>\$ 55</u>	<u>\$ (1)</u>	
As of September 1, 2016				
Yen	\$ 1,668	\$ —	\$ (10)	
Singapore dollar	206	—	—	
Euro	93	—	—	
Other	85	—	(1)	
	<u>\$ 2,052</u>	<u>\$ —</u>	<u>\$ (11)</u>	

<sup>(1)</sup> Included in receivables – other.

<sup>(2)</sup> Included in accounts payable and accrued expenses – other.

Realized and unrealized gains and losses on derivative instruments without hedge accounting designation as well as the change in the underlying monetary assets and liabilities due to changes in currency exchange rates are included in other non-operating income (expense). For derivative instruments without hedge accounting designation, we recognized net gains of \$70 million and net losses of \$47 million for the third quarter and first nine months of 2017, respectively, and net gains of \$42 million and \$113 million for the third quarter and first nine months of 2016, respectively.

## Derivative Instruments with Cash Flow Hedge Accounting Designation

**Currency Derivatives:** We utilize currency forward contracts that generally mature within 12 months to hedge our exposure to changes in cash flows from changes in currency exchange rates for certain capital expenditures. Currency forward contracts are measured at fair value based on market-based observable inputs including currency exchange spot and forward rates, interest rates, and credit-risk spreads (Level 2).

For derivative instruments designated as cash flow hedges, the effective portion of the realized and unrealized gain or loss on the derivatives is included as a component of accumulated other comprehensive income (loss). Amounts in accumulated other comprehensive income (loss) are reclassified into earnings in the same line items and in the same periods in which the underlying transactions affect earnings. The ineffective and excluded portion of the realized and unrealized gain or loss is included in other non-operating income (expense). Total notional amounts and gross fair values for derivative instruments with cash flow hedge accounting designation were as follows:

	Notional Amount (in U.S. Dollars)	Fair Value	
		Current Assets <sup>(1)</sup>	Current Liabilities <sup>(2)</sup>
As of June 1, 2017			
Euro	\$ 129	\$ 5	\$ —
Yen	86	1	(1)
	<u>\$ 215</u>	<u>\$ 6</u>	<u>\$ (1)</u>
As of September 1, 2016			
Euro	\$ 65	\$ —	\$ (1)
Yen	107	2	(1)
	<u>\$ 172</u>	<u>\$ 2</u>	<u>\$ (2)</u>

<sup>(1)</sup> Included in receivables – other.

<sup>(2)</sup> Included in accounts payable and accrued expenses – other.

We recognized a gain in accumulated other comprehensive income (loss) from the effective portion of cash flow hedges of \$6 million in the third quarter and a loss of \$3 million in the first nine months of 2017, and gains of \$4 million and \$5 million in the third quarter and first nine months of 2016, respectively. Neither the ineffective portions of cash flow hedges recognized in other non-operating income (expense) nor amounts reclassified from accumulated other comprehensive income (loss) to earnings were material in the third quarters and first nine months 2017 and 2016. The amounts from cash flow hedges included in accumulated other comprehensive income (loss) that are expected to be reclassified into earnings in the next 12 months are not material.

## **Equity Plans**

As of June 1, 2017, 100 million shares were available for future awards under our equity plans.

## Stock Options

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Stock options granted	1	1	7	8
Weighted-average grant-date fair value per share	\$ 11.64	\$ 4.92	\$ 8.59	\$ 6.96
Average expected life in years	5.5	5.6	5.5	5.5
Weighted-average expected volatility	44%	51%	46%	47%
Weighted-average risk-free interest rate	2.0%	1.3%	1.8%	1.7%
Expected dividend yield	0%	0%	0%	0%



**Restricted Stock and Restricted Stock Units ("Restricted Stock Awards")**

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Restricted stock awards granted	—	—	8	9
Weighted-average grant-date fair value per share	\$ 27.75	\$ 10.35	\$ 19.10	\$ 15.75

**Stock-based Compensation Expense**

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Stock-based compensation expense by caption				
Cost of goods sold	\$ 24	\$ 21	\$ 66	\$ 58
Selling, general, and administrative	20	14	53	52
Research and development	13	12	39	38
	<u>\$ 57</u>	<u>\$ 47</u>	<u>\$ 158</u>	<u>\$ 148</u>
Stock-based compensation expense by type of award				
Stock options	\$ 19	\$ 19	\$ 54	\$ 61
Restricted stock awards	38	28	104	87
	<u>\$ 57</u>	<u>\$ 47</u>	<u>\$ 158</u>	<u>\$ 148</u>

As of June 1, 2017, \$402 million of total unrecognized compensation costs for unvested awards was expected to be recognized through the third quarter of 2021, resulting in a weighted-average period of 1.2 years. Stock-based compensation expense does not reflect significant income tax benefits, which is consistent with our treatment of income or loss from our U.S. operations.

**Restructure and Asset Impairments**

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
2016 Restructuring Plan	\$ —	\$ —	\$ 33	\$ —
Other	12	—	12	16
	<u>\$ 12</u>	<u>\$ —</u>	<u>\$ 45</u>	<u>\$ 16</u>

In the fourth quarter of 2016, we initiated a restructure plan in response to business conditions and the need to accelerate focus on our key priorities (the "2016 Restructuring Plan"). The 2016 Restructuring Plan includes the elimination of certain projects and programs, the permanent closure of a number of open headcount requisitions, workforce reductions in certain areas of our business, and other non-headcount related spending reductions. As a result, we incurred charges of \$33 million in the first nine months of 2017 and \$58 million in the fourth quarter of 2016 and do not expect to incur additional material charges. As of September 1, 2016, we had accrued liabilities of \$24 million related to the 2016 Restructuring Plan, substantially all of which was paid in the first nine months of 2017.

On April 14, 2017, we entered into an agreement to sell our assembly and test facility located in Akita, Japan and our 40% ownership interest in Tera Probe, for aggregate consideration of \$60 million, substantially all in cash, subject to changes in working capital. We completed the sale of our interest in Tera Probe in the third quarter of 2017 and expect to close the sale of the Akita facility in the fourth quarter of 2017. We recognized a loss of \$11 million in the third quarter of 2017 for this transaction and do not expect to incur additional material charges.

## Other Non-Operating Income (Expense), Net

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Loss on restructure of debt	\$ (61)	\$ (3)	\$ (63)	\$ (4)
Loss from changes in currency exchange rates	(22)	(5)	(62)	(13)
Gain on remeasurement of previously-held equity interest in Inotera	—	—	71	—
Other	—	(26)	(9)	(27)
	<u>\$ (83)</u>	<u>\$ (34)</u>	<u>\$ (63)</u>	<u>\$ (44)</u>

In the third quarter of 2016, we recognized other non-operating expense of \$30 million to write off indemnification receivables upon the resolution of uncertain tax positions.

## Income Taxes

Our income tax (provision) benefit consisted of the following:

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Utilization of and other changes in net deferred tax assets of MMJ, MMT, and Inotera	\$ (31)	\$ (71)	\$ (52)	\$ (103)
U.S. valuation allowance release resulting from business acquisition	—	—	—	41
Other income tax (provision) benefit, primarily other non-U.S. operations	(61)	56	(109)	46
	<u>\$ (92)</u>	<u>\$ (15)</u>	<u>\$ (161)</u>	<u>\$ (16)</u>

Other income tax (provision) benefit in the table above for the third quarter and first nine months of 2016 included tax benefits of \$52 million and \$58 million, respectively, related to the favorable resolution of certain prior year tax matters, which were previously reserved as uncertain tax positions.

We have a full valuation allowance for our net deferred tax assets associated with our U.S. operations. The amount of the deferred tax assets considered realizable could be adjusted if significant positive evidence increases. Income taxes on U.S. operations in the third quarters and first nine months of 2017 and 2016 were substantially offset by changes in the valuation allowance.

As of the date of the Inotera Acquisition, Inotera's net operating loss carryforwards were \$654 million, which expire on various dates through 2022. In connection with the Inotera Acquisition, we assumed \$54 million of uncertain tax positions, of which \$26 million was recorded in purchase accounting as a reduction to deferred tax assets. The amounts recorded in purchase accounting primarily related to the surtax treatment of certain purchase accounting adjustments. During the second quarter of 2017, \$21 million of the uncertain tax positions assumed in the Inotera Acquisition reached effective settlement with no impact to tax expense or purchase accounting. Although the timing of final resolution is uncertain, the estimated potential reduction in the Inotera unrecognized tax benefits in the next 12 months ranges from \$0 to \$36 million, including interest and penalties.

We operate in a number of tax jurisdictions, including Singapore and Taiwan, where our earnings are indefinitely reinvested and are taxed at lower effective tax rates than the U.S. statutory rate and in a number of locations outside the U.S., including Singapore, where we have tax incentive arrangements that are conditional, in part, upon meeting certain business operations and employment thresholds. The effect of tax incentive arrangements, which expire in whole or in part at various dates through 2030, reduced our tax provision for the third quarter and first nine months of 2017 by \$250 million (benefitting our diluted earnings per share by \$0.21) and \$422 million (\$0.37 per diluted share), respectively, and were not material for the third quarter or first nine months of 2016.

## Earnings Per Share

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Net income (loss) available to Micron – Basic and Diluted	\$ 1,647	\$ (215)	\$ 2,721	\$ (106)
Weighted-average common shares outstanding – Basic	1,106	1,036	1,082	1,035
Dilutive effect of equity plans and convertible notes	71	—	60	—
Weighted-average common shares outstanding – Diluted	1,177	1,036	1,142	1,035
Earnings (loss) per share				
Basic	\$ 1.49	\$ (0.21)	\$ 2.52	\$ (0.10)
Diluted	1.40	(0.21)	2.38	(0.10)

Antidilutive potential common shares that could dilute basic earnings per share in the future were 52 million and 59 million for the third quarter and first nine months of 2017, respectively, and 184 million for the third quarter and first nine months of 2016.

## Segment Information

Segment information reported herein is consistent with how it is reviewed and evaluated by our chief operating decision maker. We have the following four business units, which are our reportable segments:

**Compute and Networking Business Unit ("CNBU"):** Includes memory products sold into compute, networking, graphics, and cloud server markets.

**Storage Business Unit ("SBU"):** Includes memory products sold into enterprise, client, cloud, and removable storage markets. SBU also includes products sold to Intel through our IMFT joint venture.

**Mobile Business Unit ("MBU"):** Includes memory products sold into smartphone, tablet, and other mobile-device markets.

**Embedded Business Unit ("EBU"):** Includes memory products sold into automotive, industrial, connected home, and consumer electronics markets.

Certain operating expenses directly associated with the activities of a specific segment are charged to that segment. Other indirect operating expenses (income) are generally allocated to segments based on their respective percentage of cost of goods sold or forecasted wafer production. In the first quarter of 2017, we revised the measure of segment profitability reviewed by our chief operating decision maker and, as a result, certain items are no longer allocated to our business units. Comparative periods have been revised to reflect these changes. Items not allocated are identified in the table below.

We do not identify or report internally our assets (other than goodwill) or capital expenditures by segment, nor do we allocate gains and losses from equity method investments, interest, other non-operating income or expense items, or taxes to segments.

	Quarter ended		Nine months ended	
	June 1, 2017	June 2, 2016	June 1, 2017	June 2, 2016
Net sales				
CNBU	\$ 2,389	\$ 1,090	\$ 5,776	\$ 3,282
SBU	1,316	719	3,217	2,504
MBU	1,129	561	3,243	1,898
EBU	700	487	1,868	1,426
All Other	32	41	80	72
	<u>\$ 5,566</u>	<u>\$ 2,898</u>	<u>\$ 14,184</u>	<u>\$ 9,182</u>
Operating income				
CNBU	\$ 1,219	\$ (42)	\$ 2,159	\$ (35)
SBU	276	(49)	302	(66)
MBU	304	(6)	563	132
EBU	256	115	627	332
All Other	16	13	35	21
	<u>2,071</u>	<u>31</u>	<u>3,686</u>	<u>384</u>
Unallocated				
Flow-through of Inotera inventory step up	(36)	—	(96)	—
Stock-based compensation	(57)	(47)	(158)	(148)
Restructure and asset impairments	(12)	—	(45)	(16)
Other	(3)	(11)	(21)	(20)
	<u>(108)</u>	<u>(58)</u>	<u>(320)</u>	<u>(184)</u>
Operating income (loss)	<u>\$ 1,963</u>	<u>\$ (27)</u>	<u>\$ 3,366</u>	<u>\$ 200</u>

### Certain Concentrations

Net sales to Kingston for the first nine months of 2017 were 10% of total net sales and no other customer exceeded 10%.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*The following discussion contains trend information and other forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements such as those made regarding benefits from the Inotera Acquisition; the effect on 2017 depreciation expense from changes to estimated useful lives; effects of inventory step-up in connection with the Inotera Acquisition; future restructure charges; timing of the sale of the Akita facility; our expectation, from time to time, to engage in additional financing transactions; the sufficiency of our cash and investments, cash flows from operations, and available financing to meet our requirements for at least the next 12 months; capital spending in 2017; and the timing of payments for certain contractual obligations. We are under no obligation to update these forward-looking statements. Our actual results could differ materially from our historical results and those discussed in the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, those identified in "Part II Other Information – Item 1A. Risk Factors." This discussion should be read in conjunction with the consolidated financial statements and accompanying notes for the year ended September 1, 2016. All period references are to our fiscal periods unless otherwise indicated. Our fiscal year is the 52 or 53-week period ending on the Thursday closest to August 31. Our fiscal 2017 and 2016 each contain 52 weeks. All production data includes the production of IMFT and Inotera. All tabular dollar amounts are in millions except per share amounts.*

Our Management's Discussion and Analysis is provided in addition to the accompanying consolidated financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. This discussion is organized as follows:

- **Overview:** Overview of our operations, business, and highlights of key events.
- **Results of Operations:** An analysis of our financial results consisting of the following:
  - Consolidated results;
  - Operating results by business segment;
  - Operating results by product; and
  - Operating expenses and other.
- **Liquidity and Capital Resources:** An analysis of changes in our balance sheet and cash flows and discussion of our financial condition and liquidity.
- **Recently Adopted and Issued Accounting Standards**

### Overview

We are a world leader in innovative memory solutions. Through our global brands – Micron, Crucial, Lexar, and Ballistix – our broad portfolio of high-performance memory technologies, including DRAM, NAND, NOR Flash, and 3D XPoint memory, is transforming how the world uses information. Backed by more than 35 years of technology leadership, our memory solutions enable the world's most innovative computing, consumer, enterprise storage, data center, mobile, embedded, and automotive applications. We market our products through our internal sales force, independent sales representatives, and distributors primarily to original equipment manufacturers and retailers located around the world. We face intense competition in the semiconductor memory market and in order to remain competitive we must continuously develop and implement new technologies and decrease manufacturing costs. Our success is largely dependent on market acceptance of our diversified portfolio of semiconductor products, efficient utilization of our manufacturing infrastructure, successful ongoing development of advanced product and process technologies, and generating a return on R&D investments.

## Acquisition of Inotera

Through December 6, 2016, we held a 33% ownership interest in Inotera, now known as Micron Technology Taiwan, Inc. ("MTTW"), Nanya and certain of its affiliates held a 32% ownership interest, and the remaining ownership interest was publicly held. On December 6, 2016, we acquired the 67% interest in Inotera not owned by us (the "Inotera Acquisition") and began consolidating Inotera's operating results. The cash paid for the Inotera Acquisition was funded with 80 billion New Taiwan dollars of proceeds from the 2021 MSTW Term Loan, \$986 million of proceeds from the sale of 58 million shares of our common stock to Nanya, and cash on hand. Inotera manufactures DRAM products at its 300mm wafer fabrication facility in Taoyuan City, Taiwan, and sold such products exclusively to us through supply agreements. As a result of the Inotera Acquisition, we expect to experience greater operational flexibility to drive new technology in products manufactured by Inotera, optimize the deployment of our cash flows across our operations, and enhance our ability to adapt our product offerings to changes in market conditions. In connection with the Inotera Acquisition, we revalued our previously-held 33% equity interest to its fair value and recognized a non-operating gain of \$71 million in the second quarter of 2017.

## Results of Operations

### Consolidated Results

	Third Quarter				Second Quarter		Nine Months			
	2017	% of Net Sales	2016	% of Net Sales	2017	% of Net Sales	2017	% of Net Sales	2016	% of Net Sales
Net sales	\$ 5,566	100 %	\$ 2,898	100 %	\$ 4,648	100 %	\$ 14,184	100 %	\$ 9,182	100 %
Cost of goods sold	2,957	53 %	2,400	83 %	2,944	63 %	8,860	62 %	7,256	79 %
Gross margin	2,609	47 %	498	17 %	1,704	37 %	5,324	38 %	1,926	21 %
SG&A	204	4 %	148	5 %	187	4 %	550	4 %	502	5 %
R&D	434	8 %	382	13 %	473	10 %	1,377	10 %	1,206	13 %
Restructure and asset impairments	12	— %	—	— %	4	— %	45	— %	16	— %
Other operating (income) expense, net	(4)	— %	(5)	— %	(4)	— %	(14)	— %	2	— %
Operating income (loss)	1,963	35 %	(27)	(1)%	1,044	22 %	3,366	24 %	200	2 %
Interest income (expense), net	(143)	(3)%	(99)	(3)%	(153)	(3)%	(428)	(3)%	(269)	(3)%
Other non-operating income (expense), net	(83)	(1)%	(34)	(1)%	34	1 %	(63)	— %	(44)	— %
Income tax (provision) benefit	(92)	(2)%	(15)	(1)%	(38)	(1)%	(161)	(1)%	(16)	— %
Equity in net income (loss) of equity method investees	2	— %	(40)	(1)%	7	— %	7	— %	24	— %
Net income attributable to noncontrolling interests	—	— %	—	— %	—	— %	—	— %	(1)	— %
Net income (loss) attributable to Micron	<u>\$ 1,647</u>	30 %	<u>\$ (215)</u>	(7)%	<u>\$ 894</u>	19 %	<u>\$ 2,721</u>	19 %	<u>\$ (106)</u>	(1)%

## Net Sales

	Third Quarter				Second Quarter		Nine Months			
	2017	% of Total	2016	% of Total	2017	% of Total	2017	% of Total	2016	% of Total
CNBU	\$ 2,389	43%	\$ 1,090	38%	\$ 1,917	41%	\$ 5,776	41%	\$ 3,282	36%
SBU	1,316	24%	719	25%	1,041	22%	3,217	23%	2,504	27%
MBU	1,129	20%	561	19%	1,082	23%	3,243	23%	1,898	21%
EBU	700	13%	487	17%	590	13%	1,868	13%	1,426	16%
All Other	32	1%	41	1%	18	—%	80	1%	72	1%
	<u>\$ 5,566</u>		<u>\$ 2,898</u>		<u>\$ 4,648</u>		<u>\$ 14,184</u>		<u>\$ 9,182</u>	

Percentages of total net sales reflect rounding and may not total 100%.

Total net sales for the third quarter of 2017 increased 20% as compared to the second quarter of 2017. Higher sales for all operating segments resulted primarily from increases in average selling prices and gigabits sold due to increases in market demand.

Total net sales for the third quarter of 2017 increased 92% as compared to the third quarter of 2016 primarily due to increases in DRAM and Trade NAND gigabits sold and increases in average selling prices for DRAM products. Total net sales for the first nine months of 2017 increased 54% as compared to the first nine months of 2016 primarily due to increases in gigabits sold and increases in average selling prices for DRAM products, partially offset by declines in average selling prices for Trade NAND products. The increases in gigabits sold for the third quarter and first nine months of 2017 were primarily attributable to increases in market demand and higher manufacturing output due to improvements in product and process technologies.

## Gross Margin

Our overall gross margin percentage increased to 47% for the third quarter of 2017 from 37% for the second quarter of 2017 reflecting increases for all operating segments primarily due to increases in average selling prices and manufacturing cost reductions.

Our overall gross margin percentage increased to 47% for the third quarter of 2017 from 17% for the third quarter of 2016 reflecting improvements for all operating segments, primarily due to manufacturing cost reductions for DRAM and Trade NAND products and increases in average selling prices for DRAM products. Our overall gross margin percentage increased to 38% for the first nine months of 2017 from 21% for the first nine months of 2016 reflecting increases in the gross margin percentages for all operating segments primarily due to manufacturing cost reductions.

Due to the lengthening period of time between DRAM product technology node transitions, an increased re-use rate of equipment, and industry trends, in the fourth quarter of 2016, we revised the estimated useful lives of equipment in our DRAM wafer fabrication facilities from five to seven years, which reduced depreciation costs by approximately \$100 million per quarter in 2017.

From January 2013 through December 2015, we purchased all of Inotera's DRAM output under supply agreements at prices reflecting discounts from market prices for our comparable components. After December 2015 through our acquisition of Inotera on December 6, 2016, the price for DRAM products purchased by us was based on a formula that equally shared margin between Inotera and us. We purchased \$504 million and \$348 million of DRAM products from Inotera in the first quarter of 2017 and third quarter of 2016, respectively. DRAM products produced by the acquired Inotera fabrication facility accounted for 39% of our aggregate DRAM gigabit production for the third quarter of 2017 as compared to 37% for the second quarter of 2017 and 32% for the third quarter of 2016. In accounting for the Inotera Acquisition, Inotera's work in process inventories were recorded at fair value, based on their estimated future selling prices, estimated costs to complete, and other factors, which was approximately \$107 million higher than the cost of work in process inventory recorded by Inotera prior to the acquisition. Of this amount, \$36 million and \$60 million were included in cost of goods sold for the third and second quarters of 2017, respectively.

## **Operating Results by Business Segments**

In the first quarter of 2017, we revised the measure of segment profitability reviewed by our chief operating decision maker and, as a result, certain items are no longer allocated to our business units. Comparative periods have been revised to reflect these changes. (See "Item 1. Financial Statements – Notes to Consolidated Financial Statements – Segment Information.")

### ***CNBU***

	<b>Third Quarter</b>		<b>Second Quarter</b>		<b>Nine Months</b>	
	<b>2017</b>	<b>2016</b>	<b>2017</b>	<b>2017</b>	<b>2016</b>	
Net sales	\$ 2,389	\$ 1,090	\$ 1,917	\$ 5,776	\$ 3,282	
Operating income (loss)	1,219	(42)	736	2,159	(35)	

CNBU sales and operating results are significantly impacted by average selling prices, gigabit sales volumes, and cost per gigabit of our DRAM products. (See "Operating Results by Product – DRAM" for further detail.) CNBU sales for the third quarter of 2017 increased 25% as compared to the second quarter of 2017 primarily due to increases in average selling prices and increases in gigabits sold as a result of favorable market conditions, particularly in enterprise, cloud, client, and networking markets. CNBU operating income for the third quarter of 2017 increased from the second quarter of 2017 due to increases in average selling prices and manufacturing cost reductions.

CNBU sales for the third quarter and first nine months of 2017 increased 119% and 76%, respectively, as compared to the corresponding periods of 2016 primarily due to increases in average selling prices and gigabits sold. CNBU operating margin for the third quarter and first nine months of 2017 improved from the corresponding periods of 2016 primarily due to increases in average selling prices and manufacturing cost reductions.

### ***SBU***

	<b>Third Quarter</b>		<b>Second Quarter</b>		<b>Nine Months</b>	
	<b>2017</b>	<b>2016</b>	<b>2017</b>	<b>2017</b>	<b>2016</b>	
Net sales	\$ 1,316	\$ 719	\$ 1,041	\$ 3,217	\$ 2,504	
Operating income (loss)	276	(49)	71	302	(66)	

SBU sales and operating results are significantly impacted by average selling prices, gigabit sales volumes, and cost per gigabit of our Trade NAND products. (See "Operating Results by Product – Trade NAND" for further details.) SBU sales for the third quarter of 2017 increased 26% from the second quarter of 2017 primarily due to increases in gigabits sold and average selling prices. SBU sales included Non-Trade sales of \$138 million, \$158 million, and \$120 million, for the third quarter of 2017, second quarter of 2017, and third quarter of 2016, respectively.

SBU sales of Trade NAND products for the third quarter of 2017 increased 29% from the second quarter of 2017 primarily due to increases in gigabits sold and average selling prices as a result of strong market demand, particularly for SSD products in the cloud and enterprise markets, combined with higher manufacturing output. SBU operating income for the third quarter of 2017 increased from the second quarter of 2017 primarily due to increases in average selling prices and manufacturing cost reductions.

SBU sales of Trade NAND products for the third quarter and first nine months of 2017 increased 91% and 30%, respectively, as compared to the corresponding periods of 2016 primarily due to increases in gigabits sold as a result of strong demand combined with higher manufacturing output, partially offset by declines in average selling prices. SBU operating margin for the third quarter and first nine months of 2017 improved from the corresponding periods of 2016 as manufacturing cost reductions outpaced declines in average selling prices, partially offset by increases in operating expenses.



**MBU**

	Third Quarter		Second Quarter	Nine Months	
	2017	2016	2017	2017	2016
Net sales	\$ 1,129	\$ 561	\$ 1,082	\$ 3,243	\$ 1,898
Operating income (loss)	304	(6)	170	563	132

MBU sales are primarily composed of DRAM and Trade NAND, with mobile DRAM products accounting for a significant majority of the sales. MBU sales for the third quarter of 2017 increased 4% as compared to the second quarter of 2017 primarily due to increases in average selling prices and gigabit sales for DRAM products as a result of strong market conditions in smartphone markets to support new product launches and higher memory content per unit. MBU operating income for the third quarter of 2017 increased from the second quarter of 2017 due to manufacturing cost reductions, increases in average selling prices for DRAM products, and lower R&D costs.

MBU sales for the third quarter and first nine months of 2017 increased 101% and 71%, respectively, as compared to the corresponding periods of 2016 primarily due to significant increases in gigabits sold driven by the completion of customer qualifications and higher memory content in smartphones, partially offset by declines in average selling prices for Trade NAND products. MBU operating margin for the third quarter and first nine months of 2017 improved from the corresponding periods of 2016 primarily due to manufacturing cost reductions and higher gigabit sales, partially offset by higher R&D costs and declines in average selling prices for Trade NAND products.

**EBU**

	Third Quarter		Second Quarter	Nine Months	
	2017	2016	2017	2017	2016
Net sales	\$ 700	\$ 487	\$ 590	\$ 1,868	\$ 1,426
Operating income	256	115	193	627	332

EBU sales are composed of DRAM, Trade NAND, and NOR in decreasing order of revenue. EBU sales for the third quarter of 2017 increased 19% as compared to the second quarter of 2017 primarily due to higher sales volumes and increases in average selling prices for DRAM products as a result of strong demand in connected home, industrial, consumer, and automotive market segments. EBU operating income for the third quarter of 2017 increased from the second quarter of 2017 primarily due to manufacturing cost reductions, increases in sales volumes, and increases in average selling prices for DRAM products.

EBU sales for the third quarter and first nine months of 2017 increased 44% and 31%, respectively, as compared to the corresponding periods of 2016, primarily due to higher sales volumes of DRAM and Trade NAND products as a result of increases in demand. EBU operating income for the third quarter of 2017 increased as compared to third quarter of 2016 primarily due to manufacturing cost reductions. EBU operating income for the first nine months of 2017 increased as compared to the first nine months of 2016 as a result of manufacturing cost reductions, which outpaced declines in average selling prices, and from increases in sales volumes.

## Operating Results by Product

### Net Sales by Product

	Third Quarter				Second Quarter		Nine Months			
	2017	% of Total	2016	% of Total	2017	% of Total	2017	% of Total	2016	% of Total
DRAM	\$ 3,559	64%	\$ 1,728	60%	\$ 2,960	64%	\$ 8,940	63%	\$ 5,261	57%
Trade NAND	1,706	31%	908	31%	1,412	30%	4,390	31%	3,125	34%
Non-Trade	138	2%	120	4%	158	3%	419	3%	372	4%
Other	163	3%	142	5%	118	3%	435	3%	424	5%
	<u>\$ 5,566</u>		<u>\$ 2,898</u>		<u>\$ 4,648</u>		<u>\$ 14,184</u>		<u>\$ 9,182</u>	

Percentages of total net sales reflect rounding and may not total 100%.

Non-Trade primarily consists of NAND and 3D XPoint products manufactured and sold to Intel through IMFT at long-term negotiated prices approximating cost. Information regarding products that combine both NAND and DRAM components is reported within Trade NAND. Other includes sales of NOR and trade 3D XPoint products.

### DRAM

	Third Quarter 2017 Versus		First Nine Months 2017 Versus
	Second Quarter 2017	Third Quarter 2016	First Nine Months 2016
	(percentage change from period indicated)		
Net sales	20 %	106 %	70 %
Average selling prices per gigabit	14 %	37 %	6 %
Gigabits sold	5 %	51 %	60 %
Cost per gigabit	(7)%	(22)%	(22)%

The increases in gigabits sold for the third quarter of 2017 as compared to the second quarter of 2017 were primarily due to strong demand across key markets and customer qualifications combined with increases in gigabit production. The increases in gigabits sold for the third quarter and first nine months of 2017 as compared to the corresponding periods of 2016 were primarily due to strong demand across key markets and customer qualifications combined with increases in gigabit production. The decreases in cost per gigabit for the third quarter of 2017 as compared to the second quarter of 2017 and third quarter of 2016 were primarily due to improvements in product and process technologies. The decreases in cost per gigabit for the third quarter and first nine months of 2017 as compared to the corresponding periods of 2016 also reflected lower depreciation due to the change made in the fourth quarter of 2016 in estimated useful lives for equipment at our DRAM wafer fabrication facilities. Gigabit production and cost reductions for the third and second quarters of 2017 were affected by a transition to a higher mix of DDR4 products, which have larger die sizes and fewer bits per wafer.

Our DRAM gross margin percentage for the third quarter of 2017 increased as compared to the second quarter of 2017 and third quarter of 2016 primarily due to increases in average selling prices and manufacturing cost reductions. Our gross margin percentage on sales of DRAM products for the first nine months of 2017 improved from the first nine months of 2016 primarily due to manufacturing cost reductions and increases in average selling prices.

## Trade NAND

	Third Quarter 2017 Versus		First Nine Months 2017 Versus
	Second Quarter 2017	Third Quarter 2016	First Nine Months 2016
	(percentage change from period indicated)		
Net sales	21 %	88 %	40 %
Average selling prices per gigabit	3 %	(4)%	(13)%
Gigabits sold	17 %	94 %	61 %
Cost per gigabit	(12)%	(31)%	(26)%

The increase in gigabits sold of Trade NAND for the third quarter of 2017 as compared to the second quarter of 2017 and third quarter of 2016 was due to increases in demand from strong market conditions, particularly for SSD products. Our ability to meet this demand was due in part to an increase in production, primarily due to the ramp of additional capacity and improvements in product and process technology, including our transition to 3D NAND products.

Our gross margin percentage on sales of Trade NAND products for the third quarter of 2017 increased from the second quarter of 2017 primarily due to manufacturing cost reductions and increases in average selling prices. Our gross margin percentage on sales of Trade NAND products for the third quarter and first nine months of 2017 improved from the corresponding periods of 2016 as manufacturing cost reductions outpaced declines in average selling prices.

### Operating Expenses and Other

#### *Selling, General, and Administrative*

SG&A expenses for the third quarter of 2017 were 9% higher than the second quarter of 2017 primarily due to increases in legal fees and payroll costs, partially offset by decreases of transaction costs related to the Inotera Acquisition. SG&A expenses for the third quarter of 2017 were 38% higher than the third quarter of 2016 primarily due to increases in variable pay and legal fees. SG&A expenses for the first nine months of 2017 were 10% higher as compared to the first nine months of 2016 primarily due to increases in variable pay and transaction costs related to the Inotera Acquisition.

#### *Research and Development*

R&D expenses for the third quarter of 2017 were 8% lower than the second quarter of 2017 primarily due to lower volumes of development wafers processed. R&D expenses for the third quarter of 2017 were 14% higher than for the third quarter of 2016 primarily due to higher volumes of development wafers processed and increases in variable pay. R&D expenses for the first nine months of 2017 were 14% higher than the first nine months of 2017 primarily due to higher volumes of development wafers processed and increases in variable pay.

We generally share with Intel the costs of product design and process development activities for NAND and 3D XPoint memory at IMFT and our other facilities. Our R&D expenses reflect net reductions as a result of reimbursements under our cost-sharing arrangements with Intel and others of \$47 million for the third quarter of 2017, \$59 million for the second quarter of 2017, and \$55 million for the third quarter of 2016.

## Income Taxes

Our income tax (provision) benefit consisted of the following:

	Third Quarter		Second Quarter		Nine Months	
	2017	2016	2017	2017	2016	
Utilization of and other changes in net deferred tax assets of MMJ, MMT, and Inotera	\$ (31)	\$ (71)	\$ (8)	\$ (52)	\$ (103)	
U.S. valuation allowance release resulting from business acquisition	—	—	—	—	41	
Other income tax (provision) benefit, primarily other non-U.S. operations	(61)	56	(30)	(109)	46	
	<u>\$ (92)</u>	<u>\$ (15)</u>	<u>\$ (38)</u>	<u>\$ (161)</u>	<u>\$ (16)</u>	
Effective tax rate	5.3%	(9.4)%	4.1%	5.6%	(14.2)%	

Other income tax (provision) benefit in the table above for the third quarter and first nine months of 2016 included tax benefits of \$52 million and \$58 million, respectively, related to the favorable resolution of certain prior year tax matters, which were previously reserved as uncertain tax positions.

Our effective tax rates reflect the following:

- operations in tax jurisdictions, including Singapore and Taiwan, where our earnings are indefinitely reinvested and the tax rates are significantly lower than the U.S. statutory rate;
- operations outside the U.S., including Singapore, where we have tax incentive arrangements that further decrease our effective tax rates; and
- a valuation allowance against substantially all of our U.S. net deferred tax assets.

We operate in a number of locations outside the U.S., including Singapore, where we have tax incentive arrangements that are conditional, in part, upon meeting certain business operation and employment thresholds. The effect of tax incentive arrangements, which expire in whole or in part at various dates through 2030, reduced our tax provision by \$250 million (benefitting our diluted earnings per share by \$0.21) for the third quarter of 2017, \$132 million (\$0.11 per diluted share) for the second quarter of 2017, and were not material to our tax provision for the third quarter of 2016.

## Equity in Net Income (Loss) of Equity Method Investees

Equity in net income (loss) of equity method investees, net of tax, included the following:

	Third Quarter		Second Quarter		Nine Months	
	2017	2016	2017	2017	2016	
Inotera	\$ —	\$ (19)	\$ —	\$ 9	\$ 35	
Tera Probe	2	(22)	7	(3)	(16)	
Other	—	1	—	1	5	
	\$ 2	\$ (40)	\$ 7	\$ 7	\$ 24	

We ceased recognizing our share of Tera Probe's earnings due to our sale of our equity interest in Tera Probe in the third quarter of 2017. In addition, we ceased recognizing our share of Inotera's earnings due to our acquisition of the remaining interest in Inotera on December 6, 2016. In the first quarter of 2017 and third quarter of 2016, we recorded impairment charges of \$16 million and \$25 million, respectively, within equity in net income (loss) of equity method investees to write down the carrying value of our investment in Tera Probe to its then fair value in each of those periods based on its trading price.

## Other

Net interest expense increased 44% and 59% for the third quarter and first nine months of 2017 as compared to the corresponding periods of 2016 primarily due to increases in debt obligations, including our borrowings of 80 billion New Taiwan dollars at an effective interest rate of 3.02% on December 6, 2016 under the 2021 MSTW Term Loan and \$1.25 billion at an effective interest rate of 7.69% on April 26, 2016 under the 2023 Secured Notes.

Further discussion of other operating and non-operating income and expenses can be found in the following notes contained in "Item 1. Financial Statements – Notes to Consolidated Financial Statements":

- Equity Plans
- Restructure and Asset Impairments
- Other Non-Operating Income (Expense), Net

## Liquidity and Capital Resources

Our primary sources of liquidity are cash generated from operations and financing obtained from capital markets. Cash generated from operations is highly dependent on selling prices for our products, which can vary significantly from period to period. We are continuously evaluating alternatives for efficiently funding our capital expenditures and ongoing operations. We expect, from time to time in the future, to engage in a variety of financing transactions for such purposes, including the issuance of securities. As of June 1, 2017, we had credit facilities available for up to \$925 million of additional financing, of which \$175 million was drawn on June 5, 2017, subsequent to the end of our third quarter of 2017. The remaining amount available is based, in part, on eligible receivables. We expect that our cash and investments, cash flows from operations, and available financing will be sufficient to meet our requirements through at least the next 12 months.

To develop new product and process technologies, support future growth, achieve operating efficiencies, and maintain product quality, we must continue to invest in manufacturing technologies, facilities and equipment, and R&D. We estimate that cash expenditures in 2017 for property, plant, and equipment will be approximately \$4.8 billion to \$5.2 billion, which reflects the offset of amounts we expect to be funded by our partners. The actual amounts for 2017 will vary depending on market conditions. As of June 1, 2017, we had commitments of approximately \$770 million for the acquisition of property, plant, and equipment, substantially all of which is expected to be paid within one year.

Cash and marketable investments included the following:

As of	June 1, 2017	September 1, 2016
Cash and equivalents and short-term investments	\$ 4,330	\$ 4,398
Long-term marketable investments	471	414

Our investments consist primarily of liquid investment-grade fixed-income securities, diversified among industries and individual issuers. As of June 1, 2017, \$2.62 billion of our cash and marketable investments was held by our foreign subsidiaries. To mitigate credit risk, we invest through high-credit-quality financial institutions and by policy generally limit the concentration of credit exposure by restricting the amount of investments with any single obligor.

## Acquisition of Inotera

Through December 6, 2016, we held a 33% ownership interest in Inotera, Nanya and certain of its affiliates held a 32% ownership interest, and the remaining ownership interest was publicly held. On December 6, 2016, we acquired the 67% interest in Inotera not owned by us for an aggregate of \$4.1 billion in cash. The cash paid for the Inotera Acquisition was funded with 80 billion New Taiwan dollars of proceeds from the 2021 MSTW Term Loan, \$986 million of proceeds from the sale of 58 million shares of our common stock to Nanya, and cash on hand.

## Acquisition Financing

**2021 MSTW Term Loan:** On December 6, 2016, we drew 80 billion New Taiwan dollars under a collateralized, five-year term loan that bears interest at a variable per annum rate equal to the three-month or six-month TAIBOR, at our option, plus a margin of 2.05%. Principal under the 2021 MSTW Term Loan is payable in six equal semi-annual installments, commencing in June 2019, through December 2021. The 2021 MSTW Term Loan contains financial covenants, which if not maintained, could in certain cases constitute an event of default and result in all obligations owed under the 2021 MSTW Term Loan being accelerated to be immediately due and payable. The 2021 MSTW Term Loan also contains customary events of default. The 2021 MSTW Term Loan is collateralized by certain assets and is guaranteed by Micron. To hedge our currency exposure of this borrowing, we are party to a series of currency forward contracts to purchase New Taiwan dollars under a rolling hedge strategy. As of June 1, 2017, the forward contracts expire at various dates through March 2018. See "Item 1. Financial Statements – Notes to Consolidated Financial Statements – Debt."

## Limitations on the Use of Cash and Investments

**MMJ Group:** Cash and marketable investments in the table above included an aggregate of \$595 million held by the MMJ Group as of June 1, 2017. As a result of the corporate reorganization proceedings the MMJ Companies initiated in March 2012, and for so long as such proceedings are continuing, the MMJ Companies and their subsidiaries are prohibited from paying dividends to us. In addition, pursuant to an order of the Japan Court, the MMJ Companies cannot make loans or advances, other than certain ordinary course advances, to us without the consent of the Japan Court and may, under certain circumstances, be subject to approval of the legal trustees and Japan Court. As a result, the assets of the MMJ Group are not available for use by us in our other operations. Furthermore, certain uses of the assets of the MMJ Group, including investments in certain capital expenditures and in MMT, may require consent of MMJ's trustees and/or the Japan Court.

**MSTW and MTTW:** Cash and marketable investments in the table above included an aggregate of \$261 million held by MSTW and MTTW as of June 1, 2017. The 2021 MSTW Term Loan contains covenants that limit or restrict the ability of MSTW and MTTW to pay dividends.

**IMFT:** Cash and marketable investments in the table above included \$113 million held by IMFT as of June 1, 2017. Our ability to access funds held by IMFT to finance our other operations is subject to agreement by Intel and contractual limitations. Amounts held by IMFT are not anticipated to be available to finance our other operations.

**Indefinitely Reinvested:** As of June 1, 2017, \$895 million of cash and marketable investments, including substantially all of the amounts held by the MMJ Group, MSTW, and MTTW, was held by foreign subsidiaries whose earnings were considered to be indefinitely reinvested and repatriation of these funds to the U.S. would be subject to U.S. federal income taxes. Determination of the amount of unrecognized deferred tax liabilities related to investments in these foreign subsidiaries is not practicable.

## Cash Flows

	First Nine Months	
	2017	2016
Net cash provided by operating activities	\$ 4,950	\$ 2,272
Net cash provided by (used for) investing activities	(6,239)	(1,642)
Net cash provided by (used for) financing activities	1,207	1,703
Effect of changes in currency exchange rates on cash and equivalents	(10)	7
Net increase (decrease) in cash and equivalents	\$ (92)	\$ 2,340

**Operating Activities:** For the first nine months of 2017, cash provided by operating activities was due primarily to cash generated by our operations and the effect of working capital adjustments, which included \$1.34 billion of cash used for increases in receivables, \$361 million of payments attributed to intercompany balances in connection with the Inotera Acquisition, and \$511 million of cash provided from increases in accounts payable and accrued expenses. For the first nine months of 2016, cash provided by operating activities was due primarily to cash generated by our operations and the effect of working capital adjustments, which included \$468 million of cash provided from reductions in receivables, offset by \$580 million of cash used from increases in inventory.

**Investing Activities:** For the first nine months of 2017, net cash used for investing activities consisted primarily of \$3.47 billion of expenditures for property, plant, and equipment (which excludes offsets of amounts funded by our partners) and \$2.63 billion of net cash paid for the Inotera Acquisition (net of \$361 million of payments attributed to intercompany balances with Inotera included in operating activities). For the first nine months of 2016, net cash used for investing activities consisted primarily of \$3.89 billion of expenditures for property, plant, and equipment (which excludes offsets of amounts funded by our partners) and \$148 million for our acquisition of Tidal Systems, Ltd., partially offset by \$2.31 billion of net inflows from sales, maturities, and purchases of available-for-sale securities.

**Financing Activities:** For the first nine months of 2017, net cash provided by financing activities consisted primarily of \$2.48 billion of proceeds from the 2021 MSTW Term Loan, \$620 million of proceeds from the 2021 MSAC Term Loan, partially offset by repurchases of \$952 million in aggregate principal of our 2025 Notes and 2026 Notes for an aggregate of \$1.00 billion in cash and repayments of \$774 million of other debt. For the first nine months of 2016, net cash provided by financing activities consisted primarily of \$1.25 billion from the issuance of our 2023 Senior Secured Notes, \$742 million (net of original issue discount) from the issuance of our 2022 Term Loan B notes, and \$538 million from equipment sale-leaseback financing transactions, which were partially offset by cash outflows of \$689 million for repayments of debt and \$125 million for the open-market repurchases of 7 million shares of our common stock. See "Item 1. Financial Statements – Notes to Consolidated Financial Statements – Debt."

### **Potential Settlement Obligations of Convertible Notes**

Since the closing price of our common stock for at least 20 trading days in the 30 trading day period ending on June 30, 2017 exceeded 130% of the conversion price per share of our 2032 Notes and 2033 Notes, holders may convert these notes through the calendar quarter ended September 30, 2017. The following table summarizes the potential settlements that we could be required to make for the calendar quarter ending September 30, 2017 if all holders converted their 2032 Notes and 2033 Notes. The amounts in the table below are based on our closing share price of \$30.76 as of June 1, 2017.

	Settlement Option for		Underlying Shares	If Settled With Minimum Cash Required Per the Terms of Each Note		If Settled Entirely With Cash
	Principal Amount	Amount in Excess of Principal		Cash	Remainder in Shares	
2032C Notes	Cash and/or shares	Cash and/or shares	23	\$ —	23	\$ 714
2032D Notes	Cash and/or shares	Cash and/or shares	18	—	18	546
2033E Notes	Cash	Cash and/or shares	16	173	10	486
2033F Notes	Cash	Cash and/or shares	27	297	18	836
			84	\$ 470	69	\$ 2,582

### **Contractual Obligations**

As of June 1, 2017	Payments Due by Period						
	Total	Remainder of 2017	2018	2019	2020	2021	2022 and Thereafter
Notes payable <sup>(1)(2)</sup>	\$ 13,316	\$ 182	\$ 1,009	\$ 1,533	\$ 2,053	\$ 1,567	\$ 6,972
Capital lease obligations <sup>(2)</sup>	1,442	105	394	332	228	96	287
Operating leases <sup>(3)</sup>	144	7	27	26	21	17	46
Total	\$ 14,902	\$ 294	\$ 1,430	\$ 1,891	\$ 2,302	\$ 1,680	\$ 7,305

<sup>(1)</sup> Amounts include MMJ Creditor Installment Payments, convertible notes, and other notes.

<sup>(2)</sup> Amounts include principal and interest.

<sup>(3)</sup> Amounts include contractually obligated minimum lease payments for operating leases having an initial noncancelable term in excess of one year.

The expected timing of payment amounts of the obligations discussed above is estimated based on current information. Any redemptions, repurchases, or conversions of debt could impact the amount and timing of our cash payments.

## Recently Adopted Accounting Standards

See "Item 1. Financial Statements – Notes to Consolidated Financial Statements – Recently Adopted Accounting Standards."

## Recently Issued Accounting Standards

See "Item 1. Financial Statements – Notes to Consolidated Financial Statements – Recently Issued Accounting Standards."

## ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

### Interest Rate Risk

We are exposed to interest rate risk related to our indebtedness and our investment portfolio. As of June 1, 2017 and September 1, 2016, we had debt with fixed interest rates of \$6.3 billion and \$7.5 billion, respectively. As a result, the fair value of our debt fluctuates based on changes in market interest rates. We estimate that, as of June 1, 2017 and September 1, 2016, a decrease in market interest rates of 1% would increase the fair value of our notes payable by approximately \$299 million and \$420 million, respectively. A 1% increase in the interest rates of our variable-rate debt would result in an increase in interest expense of approximately \$40 million per year.

As of June 1, 2017 and September 1, 2016, we held fixed-rate debt investment securities of \$1.16 billion and \$1.11 billion, respectively, which were subject to interest rate risk. We estimate that a 0.5% increase in market interest rates would decrease the fair value of these instruments by approximately \$1 million as of June 1, 2017 and September 1, 2016.

### Foreign Currency Exchange Rate Risk

The information in this section should be read in conjunction with the information related to changes in the currency exchange rates in "Part II. Other Information – Item 1A. Risk Factors." Changes in currency exchange rates could materially adversely affect our results of operations or financial condition.

The functional currency for all of our operations is the U.S. dollar. The substantial majority of our sales are transacted in the U.S. dollar; however, significant amounts of our debt financing, operating expenditures, and capital purchases are incurred in or exposed to other currencies, primarily the euro, New Taiwan dollar, Singapore dollar, and yen. We have established currency risk management programs for our foreign currency balances in monetary assets and liabilities to hedge against fluctuations in the fair value and volatility of future cash flows caused by changes in currency exchange rates. We generally utilize currency forward contracts in these hedging programs, which reduce, but do not entirely eliminate, the impact of currency exchange rate movements. We do not use derivative financial instruments for trading or speculative purposes.

Based on our foreign currency balances of monetary assets and liabilities, we estimate that a 10% adverse change in exchange rates versus the U.S. dollar would result in losses of approximately \$396 million as of June 1, 2017 and \$241 million as of September 1, 2016. We hedge our exposure to changes in currency exchange rates from our monetary assets and liabilities by utilizing a rolling hedge strategy for our primary currency exposures with currency forward contracts that generally mature within nine months. In addition, we have entered into foreign currency forward contracts that mature in December 2017 and December 2018 to hedge our currency exchange rate risk on certain debt. The effectiveness of our hedges is dependent, among other factors, upon our ability to accurately forecast our monetary assets and liabilities. To hedge the exposure of changes in cash flows from changes in currency exchange rates for certain capital expenditures, we utilize currency forward contracts that generally mature within 12 months. (See "Item 1. Financial Statements – Notes to Consolidated Financial Statements – Derivative Instruments.")



## ITEM 4. CONTROLS AND PROCEDURES

An evaluation was carried out under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based upon that evaluation, the principal executive officer and principal financial officer concluded that those disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including the principal executive officer and principal financial officer, to allow timely decision regarding disclosure.

On December 6, 2016, we acquired the 67% interest in Inotera not owned by us and began consolidating Inotera. As a result, we are currently integrating Inotera's operations into our overall internal control over financial reporting. Under the guidelines established by the Securities and Exchange Commission, companies are permitted to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an acquisition while integrating the acquired company, and accordingly, we expect to exclude Inotera from the assessment of internal control over financial reporting during that time.

During the quarterly period covered by this report, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II. OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

For a discussion of legal proceedings, see "Part I – Item 3. Legal Proceedings" of our Form 10-K for 2016 and "Part I. Financial Information – Item 1. Financial Statements – Notes to Consolidated Financial Statements – Contingencies" and "Item 1A. Risk Factors" herein.

### ITEM 1A. RISK FACTORS

In addition to the factors discussed elsewhere in this Form 10-Q, the following are important factors which could cause actual results or events to differ materially from those contained in any forward-looking statements made by us. The order of these factors is not necessarily indicative of the level of risk that each poses to us. Our operations could also be affected by other factors that are presently unknown to us or not considered significant. The factors below could materially adversely affect our business, financial condition, results of operations, and stock price.

**We have experienced dramatic declines in average selling prices for our semiconductor memory products which have adversely affected our business.**

If average selling prices for our memory products decrease faster than we can decrease per gigabit costs, our business, results of operations, or financial condition could be materially adversely affected. We have experienced significant decreases in our average selling prices per gigabit in previous years as noted in the table below and may continue to experience such decreases in the future. In some prior periods, average selling prices for our memory products have been below our manufacturing costs and we may experience such circumstances in the future.

	DRAM	Trade NAND
	(percentage change in average selling prices)	
2016 from 2015	(35)%	(20)%
2015 from 2014	(11)%	(17)%
2014 from 2013	6 %	(23)%
2013 from 2012	(11)%	(18)%
2012 from 2011	(45)%	(55)%

**We may be unable to maintain or improve gross margins.**

Our gross margins are dependent upon continuing decreases in per gigabit manufacturing costs achieved through improvements in our manufacturing processes and product designs, including, but not limited to, process line-width, additional 3D memory layers, additional bits per cell (i.e., cell levels), architecture, number of mask layers, number of fabrication steps, and yield. In future periods, we may be unable to reduce our per gigabit manufacturing costs at sufficient levels to maintain or improve gross margins. Factors that may limit our ability to reduce costs include, but are not limited to, strategic product diversification decisions affecting product mix, the increasing complexity of manufacturing processes, difficulties in transitioning to smaller line-width process technologies, technological barriers, changes in process technologies, and new products that may require relatively larger die sizes. Per gigabit manufacturing costs may also be affected by the relatively smaller production quantities and shorter product lifecycles of certain specialty memory products.

## **The semiconductor memory industry is highly competitive.**

We face intense competition in the semiconductor memory market from a number of companies, including Intel; Samsung Electronics Co., Ltd.; SK Hynix Inc.; Toshiba Corporation; and Western Digital Corporation. Some of our competitors are large corporations or conglomerates that may have greater resources to invest in technology, capitalize on growth opportunities, and withstand downturns in the semiconductor markets in which we compete. Consolidation of industry competitors could put us at a competitive disadvantage. In addition, some governments, such as China, have provided, and may continue to provide, significant financial assistance to some of our competitors or to new entrants. Our competitors seek to increase silicon capacity, improve yields, reduce die size, and minimize mask levels in their product designs resulting in significant increases in the worldwide supply of semiconductor memory and downward pressure on prices. Increases in worldwide supply of semiconductor memory also result from semiconductor memory fab capacity expansions, either by way of new facilities, increased capacity utilization, or reallocation of other semiconductor production to semiconductor memory production. Our competitors may increase capital expenditures resulting in future increases in worldwide supply. We and some of our competitors have plans to or are constructing or ramping production at new fabrication facilities. Increases in worldwide supply of semiconductor memory, if not accompanied by commensurate increases in demand, would lead to further declines in average selling prices for our products and would materially adversely affect our business, results of operations, or financial condition. If competitors are more successful at developing or implementing new product or process technology, their products could have cost or performance advantages.

## **Debt obligations could adversely affect our financial condition.**

In recent periods, our debt levels have increased due to the capital intensive nature of our business, business acquisitions, and restructuring of our capital structure. As of June 1, 2017, we had debt with a carrying value of \$11.65 billion. As of June 1, 2017, we also had credit facilities available for up to \$925 million, of which \$175 million was drawn on June 5, 2017, subsequent to the end of our third quarter of 2017. The remaining amount available is subject to certain conditions, including outstanding balances of eligible receivables. Events and circumstances may occur which would cause us to not be able to satisfy these applicable draw-down conditions and utilize these facilities. We have incurred in the past, and expect to incur in the future, debt to finance our capital investments, business acquisitions, and restructuring of our capital structure.

Our debt obligations could adversely impact us. For example, these obligations could:

- require us to use a large portion of our cash flow to pay principal and interest on debt, which will reduce the amount of cash flow available to fund working capital, capital expenditures, acquisitions, R&D expenditures, and other business activities;
- result in certain of our debt instruments being accelerated to be immediately due and payable or being deemed to be in default if certain terms of default are triggered under cross-default and/or cross-acceleration provisions;
- result in all obligations owing under the 2021 MSTW Term Loan being accelerated to be immediately due and payable if our MSTW subsidiary fails to comply with financial covenants;
- increase the interest rate under the 2021 MSTW Term Loan if we or MSTW fails to maintain certain financial covenants;
- adversely impact our credit rating, which could increase future borrowing costs;
- limit our future ability to raise funds for capital expenditures, strategic acquisitions or business opportunities, R&D, and other general corporate requirements;
- restrict our ability to incur indebtedness, create or incur certain liens, and enter into sale-leaseback financing transactions;
- increase our vulnerability to adverse economic and semiconductor memory industry conditions;
- increase our exposure to interest rate risk from variable rate indebtedness;
- continue to dilute our earnings per share as a result of the conversion provisions in our convertible notes; and
- require us to continue to pay cash amounts substantially in excess of the principal amounts upon settlement of our convertible notes to minimize dilution of our earnings per share.

Our ability to meet our payment obligations under our debt instruments depends on our ability to generate significant cash flows in the future. This, to some extent, is subject to market, economic, financial, competitive, legislative, and regulatory factors as well as other factors that are beyond our control. There can be no assurance that our business will generate cash flow from operations, or that additional capital will be available to us, in an amount sufficient to enable us to meet our debt payment obligations and to fund other liquidity needs. If we are unable to generate sufficient cash flow to service our debt obligations, we may need to refinance or restructure our debt, sell assets, reduce or delay capital investments, or seek to raise additional capital. If we were unable to implement one or more of these alternatives, we may be unable to meet our debt payment obligations, which could have a material adverse effect on our business, results of operations, or financial condition.

**We may be unable to generate sufficient cash flows or obtain access to external financing necessary to fund our operations, make scheduled debt payments, and make adequate capital investments.**

Our cash flows from operations depend primarily on the volume of semiconductor memory sold, average selling prices, and manufacturing costs. To develop new product and process technologies, support future growth, achieve operating efficiencies, and maintain product quality, we must make significant capital investments in manufacturing technology, capital equipment, facilities, R&D, and product and process technology. We estimate that net cash expenditures in 2017 for property, plant, and equipment will be approximately \$4.8 billion to \$5.2 billion, which reflects the offset of amounts we expect to be funded by our partners. Investments in capital expenditures for the first nine months of 2017, offset by amounts funded by our partners, were \$3.62 billion. As of June 1, 2017, we had cash and marketable investments of \$4.80 billion. As of June 1, 2017, \$895 million of cash and equivalents and short-term investments, including substantially all of the cash held by the MMJ Group, MSTW, and MTTW, was held by foreign subsidiaries whose earnings were considered to be indefinitely reinvested and repatriation of these funds to the U.S. would subject these funds to U.S. federal income taxes. In addition, cash of \$113 million held by IMFT was generally not available to finance our other operations.

The 2021 MSTW Term Loan contains covenants that limit or restrict MSTW's ability to create liens in or dispose of collateral securing obligations under the 2021 MSTW Term Loan, mergers involving MSTW and/or MTTW, loans or guarantees to third parties by MTTW and/or MSTW, and MSTW's and/or MTTW's distribution of cash dividends. As a result, the assets of MSTW and/or MTTW are not available for use by us in our other operations.

As a result of the Japan Proceedings, for so long as such proceedings are continuing, the MMJ Companies are prohibited from paying dividends, including any cash dividends, to us and require that excess earnings be used in their businesses or to fund the MMJ Companies' installment payments. In addition, pursuant to an order of the Japan Court, the MMJ Companies cannot make loans or advances, other than certain ordinary course advances, to us without the consent of the Japan Court and may, under certain circumstances, be subject to approval of the legal trustees and Japan Court. As a result, the assets of the MMJ Companies are not available for use by us in our other operations. Furthermore, certain uses of the assets of the MMJ Group, including investments in certain capital expenditures and in MMT, may require consent of MMJ's trustees and/or the Japan Court.

In the past we have utilized external sources of financing when needed. As a result of our debt levels, expected debt amortization, and general economic conditions, it may be difficult for us to obtain financing on terms acceptable to us. There can be no assurance that we will be able to generate sufficient cash flows, use cash held by MMJ to fund its capital expenditures, access capital markets or find other sources of financing to fund our operations, make debt payments, and make adequate capital investments to remain competitive in terms of technology development and cost efficiency. Our inability to do the foregoing could have a material adverse effect on our business, results of operations, or financial conditions.

**Our acquisition of the remaining shares of Inotera involves numerous risks.**

On December 6, 2016, we acquired the remaining 67% interest in Inotera (the "Inotera Acquisition"). The cash paid for the Inotera Acquisition was funded with 80 billion New Taiwan dollars of proceeds from the 2021 MSTW Term Loan, \$986 million of proceeds from the sale of shares of our common stock to Nanya, and cash on hand.

In addition to the acquisition risks described elsewhere, the acquisition is expected to involve the following significant risks:

- we may be unable to realize the anticipated financial benefits of the acquisition;
- increased exposure to the DRAM market, which has historically experienced significant declines in pricing;
- increased leverage resulting from the transaction;
- higher capital expenditures in future periods;
- increased exposure to operating costs denominated in New Taiwan dollars;
- changed relationship with Nanya and its affiliated companies;
- effectiveness of internal controls and disclosure controls and procedures;
- effectiveness of environmental, health and safety, anti-corruption, human resource, and other policies or practices;
- integration issues with Inotera's manufacturing operations in Taiwan; and
- integration of business systems and processes.

Our acquisition of the remaining shares of Inotera is inherently risky and may materially adversely affect our business, results of operations, or financial condition. (See "Part I Financial Information – Item 1. Financial Statements – Notes to Consolidated Financial Statements – Acquisition of Inotera.")

**Our future success depends on our ability to develop and produce competitive new memory technologies.**

Our key semiconductor memory technologies of DRAM and NAND face technological barriers to continue to meet long-term customer needs. These barriers include potential limitations on the ability to shrink products in order to reduce costs, meet higher density requirements, and improve power consumption and reliability. To meet these requirements, we expect that new memory technologies will be developed by the semiconductor memory industry. Our competitors are working to develop new memory technologies that may offer performance and cost advantages to our existing memory technologies and render existing technologies obsolete. Accordingly, our future success may depend on our ability to develop and produce viable and competitive new memory technologies. There can be no assurance of the following:

- that we will be successful in developing competitive new semiconductor memory technologies;
- that we will be able to cost-effectively manufacture new products;
- that we will be able to successfully market these technologies; and
- that margins generated from sales of these products will allow us to recover costs of development efforts.

In 2015, we announced the development of 3D XPoint technology, which is an entirely new class of non-volatile memory. There is no assurance that our efforts to develop and market this new product technology will be successful. If our efforts to develop new semiconductor memory technologies are unsuccessful, our business, results of operations, or financial condition may be materially adversely affected.

**New product development may be unsuccessful.**

We are developing new products, including system-level memory products, which complement our traditional memory products or leverage their underlying design or process technology. We have made significant investments in product and process technologies and anticipate expending significant resources for new semiconductor product development over the next several years. The process to develop DRAM, NAND, and certain specialty memory products, requires us to demonstrate advanced functionality and performance, many times well in advance of a planned ramp of production, in order to secure design wins with our customers. There can be no assurance of the following:

- that our product development efforts will be successful;
- that we will be able to cost-effectively manufacture new products;
- that we will be able to successfully market these products;
- that we will be able to qualify new products with our customers on a timely basis; or
- that margins generated from sales of these products will allow us to recover costs of development efforts.

If our efforts to develop new products are unsuccessful, our business, results of operations, or financial condition may be materially adversely affected.

**Products that fail to meet specifications, are defective, or that are otherwise incompatible with end uses could impose significant costs on us.**

Products that do not meet specifications or that contain, or are perceived by our customers to contain, defects or that are otherwise incompatible with end uses could impose significant costs on us or otherwise materially adversely affect our business, results of operations, or financial condition. From time to time we experience problems with nonconforming, defective or incompatible products after we have shipped such products. In recent periods we have further diversified and expanded our product offerings, which could potentially increase the chance that one or more of our products could fail to meet specifications in a particular application. As a result of these problems, we could be adversely affected in several ways, including the following:

- we may be required to compensate customers for costs incurred or damages caused by defective or incompatible product and to replace products;
- we could incur a decrease in revenue or adjustment to pricing commensurate with the reimbursement of such costs or alleged damages; and
- we may encounter adverse publicity, which could cause a decrease in sales of our products.

**A determination that our products or manufacturing processes infringe the intellectual property rights of others or entering into a license agreement covering such intellectual property could materially adversely affect our business, results of operations, or financial condition.**

As is typical in the semiconductor and other high technology industries, from time to time others have asserted, and may in the future assert, that our products or manufacturing processes infringe their intellectual property rights. We are unable to predict the outcome of assertions of infringement made against us. A determination that our products or manufacturing processes infringe the intellectual property rights of others, or entering a license agreement covering such intellectual property, could result in significant liability and/or require us to make material changes to our products and/or manufacturing processes. Any of the foregoing results could have a material adverse effect on our business, results of operations, or financial condition. (See "Part I. Financial Information – Item 1. Financial Statements – Notes to Consolidated Financial Statements – Contingencies.")

We have a number of intellectual property license agreements. Some of these license agreements require us to make one-time or periodic payments. We may need to obtain additional patent licenses or renew existing license agreements in the future. We are unable to predict whether these license agreements can be obtained or renewed on acceptable terms.

**The acquisition of our ownership interest in Inotera from Qimonda has been challenged by the administrator of the insolvency proceedings for Qimonda.**

On January 20, 2011, Dr. Michael Jaffé, administrator for Qimonda insolvency proceedings, filed suit against Micron and Micron Semiconductor B.V., our Netherlands subsidiary ("Micron B.V."), in the District Court of Munich, Civil Chamber. The complaint seeks to void under Section 133 of the German Insolvency Act a share purchase agreement between Micron B.V. and Qimonda signed in fall 2008 pursuant to which Micron B.V. purchased substantially all of Qimonda's shares of Inotera Memories, Inc. (the "Inotera Shares"), representing approximately 18% of Inotera's outstanding shares, and seeks an order requiring us to re-transfer those shares to the Qimonda estate. The complaint also seeks, among other things, to recover damages for the alleged value of the joint venture relationship with Inotera and to terminate under Sections 103 or 133 of the German Insolvency Code a patent cross-license between us and Qimonda entered into at the same time as the share purchase agreement.

Following a series of hearings with pleadings, arguments, and witnesses on behalf of the Qimonda estate, on March 13, 2014, the Court issued judgments: (1) ordering Micron B.V. to pay approximately \$1 million in respect of certain Inotera shares sold in connection with the original share purchase; (2) ordering Micron B.V. to disclose certain information with respect to any Inotera Shares sold by it to third parties; (3) ordering Micron B.V. to disclose the benefits derived by it from ownership of the Inotera Shares, including in particular, any profits distributed on such shares and all other benefits; (4) denying Qimonda's claims against Micron for any damages relating to the joint venture relationship with Inotera; and (5) determining that Qimonda's obligations under the patent cross-license agreement are canceled. In addition, the Court issued interlocutory judgments ordering, among other things: (1) that Micron B.V. transfer to the Qimonda estate the Inotera Shares still owned by it and pay to the Qimonda estate compensation in an amount to be specified for any Inotera Shares sold to third parties; and (2) that Micron B.V. pay the Qimonda estate as compensation an amount to be specified for benefits derived by it from ownership of the Inotera Shares. The interlocutory judgments have no immediate, enforceable effect on us, and, accordingly, we expect to be able to continue to operate with full control of the Inotera Shares subject to further developments in the case. We have filed a notice of appeal, and the parties have submitted briefs to the appeals court.

We are unable to predict the outcome of the matter and therefore cannot estimate the range of possible loss. The final resolution of this lawsuit could result in the loss of the Inotera Shares or monetary damages, unspecified damages based on the benefits derived by Micron B.V. from the ownership of the Inotera Shares, and/or the termination of the patent cross-license, which could have a material adverse effect on our business, results of operation, or financial condition.

**Our joint ventures and strategic relationships involve numerous risks.**

We have entered into strategic relationships, including our IMFT joint venture with Intel, to manufacture products and develop new manufacturing process technologies and products. These joint ventures and strategic relationships are subject to various risks that could adversely affect the value of our investments and our results of operations. These risks include the following:

- our interests could diverge from our partners' or we may not be able to agree with partners on ongoing manufacturing and operational activities, or on the amount, timing, or nature of further investments in our joint venture;
- our joint venture partners' products may compete with our products;

- we may experience difficulties in transferring technology to joint ventures;
- we may experience difficulties and delays in ramping production at joint ventures;
- our control over the operations of our joint ventures is limited;
- we may recognize losses from our equity method investments;
- due to financial constraints, our joint venture partners may be unable to meet their commitments to us or our joint ventures and may pose credit risks for our transactions with them;
- due to differing business models or long-term business goals, we and our partners may not participate to the same extent on funding capital investments in our joint ventures;
- cash flows may be inadequate to fund increased capital requirements;
- we may experience difficulties or delays in collecting amounts due to us from our joint ventures and partners;
- the terms of our partnering arrangements may turn out to be unfavorable; and
- changes in tax, legal, or regulatory requirements may necessitate changes in the agreements with our partners.

If our joint ventures and strategic relationships are unsuccessful, our business, results of operations, or financial condition may be materially adversely affected.

**If our manufacturing process is disrupted, our business, results of operations, or financial condition could be materially adversely affected.**

We manufacture products using highly complex processes that require technologically advanced equipment and continuous modification to improve yields and performance. Difficulties in the manufacturing process or the effects from a shift in product mix can reduce yields or disrupt production and may increase our per gigabit manufacturing costs. We maintain operations and continuously implement new product and process technology at our manufacturing operations which are widely dispersed in multiple locations in several countries including the U.S., Singapore, Taiwan, Japan, Malaysia, and China. Additionally, our control over operations at IMFT is limited by our agreements with our partner. From time to time, we have experienced disruptions in our manufacturing process as a result of power outages, improperly functioning equipment, equipment failures, earthquakes, or other environmental events. If production at a fabrication facility is disrupted for any reason, manufacturing yields may be adversely affected or we may be unable to meet our customers' requirements and they may purchase products from other suppliers. This could result in a significant increase in manufacturing costs, loss of revenues, or damage to customer relationships, any of which could materially adversely affect our business, results of operations, or financial condition.

**We may incur additional restructure charges in future periods.**

In the fourth quarter of 2016, we initiated a restructure plan in response to business conditions and the need to accelerate focus on our key priorities (the "2016 Restructuring Plan"). The 2016 Restructuring Plan included the elimination of certain projects and programs, the permanent closure of a number of open headcount requisitions, workforce reductions in certain areas of the business, and other non-headcount related spending reductions. In connection with the plan, we incurred charges of \$33 million in the first nine months of 2017 and \$58 million in the fourth quarter of 2016 and do not expect to incur additional material charges. As of September 1, 2016, we had accrued liabilities of \$24 million related to the 2016 Restructuring Plan, substantially all of which was paid in the first nine months of 2017.

On April 14, 2017, we entered into an agreement to sell our assembly and test facility located in Akita, Japan and our 40% ownership interest in Tera Probe, for aggregate consideration of \$60 million, substantially all in cash, subject to changes in working capital. We completed the sale of our interest in Tera Probe in the third quarter of 2017 and expect to close the sale of the Akita facility in the fourth quarter of 2017. We recognized a loss of \$11 million in the third quarter of 2017 and do not expect to incur additional material charges.

We may not realize the expected savings or other benefits from our restructure plans and may also incur additional restructure charges or other losses associated with other initiatives in future periods. In connection with those initiatives, we could incur restructure charges, loss of production output, loss of key personnel, disruptions in our operations, and difficulties in the timely delivery of products, which could materially adversely affect our business, results of operations, or financial condition.

**The operations of the MMJ Companies are subject to continued oversight by the Japan Court during the pendency of the corporate reorganization proceedings.**

Because the plans of reorganization of the MMJ Companies provide for ongoing payments to creditors following the closing of our acquisition of MMJ, the Japan Proceedings are continuing, and the MMJ Companies remain subject to the oversight of the Japan Court and of the trustees (including a trustee designated by us, who we refer to as the business trustee, and a trustee designated by the Japan Court, who we refer to as the legal trustee), pending completion of the Japan Proceedings. The Japan Proceedings and oversight of the Japan Court are expected to continue until the final creditor payment is made under the MMJ Companies' plans of reorganization, which is scheduled to occur in December 2019, but may occur on a later date to the extent any claims of creditors remain unfixed on the final scheduled installment payment date. Although we may be able to petition the court to terminate the Japan Proceedings once two-thirds of all payments under the plans of reorganization are made, there can be no assurance that the Japan Court will grant any such petition.

During the pendency of the Japan Proceedings, the MMJ Companies are obligated to provide periodic financial reports to the Japan Court and may be required to obtain the consent of the Japan Court prior to taking a number of significant actions relating to their businesses, including transferring or disposing of, or acquiring, certain material assets, incurring or guaranteeing material indebtedness, settling disputes, or entering into certain material agreements. The consent of the legal trustee may also be required for matters that would likely have a material impact on the operations or assets of the MMJ Companies and their subsidiaries or for transfers of material assets, to the extent the matters or transfers would reasonably be expected to materially and adversely affect execution of the plans of reorganization of the MMJ Companies. Accordingly, during the pendency of the Japan Proceedings, our ability to effectively operate the MMJ Companies as part of our global operations or to cause the MMJ Companies to take certain actions that we deem advisable for their businesses could be adversely affected if the Japan Court or the legal trustee is unwilling to consent to various actions that we may wish to take with respect to the MMJ Companies.

**Changes in foreign currency exchange rates could materially adversely affect our business, results of operations, or financial condition.**

Across our global operations, significant transactions and balances are denominated in currencies other than the U.S. dollar (our reporting currency), primarily the euro, Singapore dollar, New Taiwan dollar, and yen. We recorded net losses from changes in currency exchange rates of \$62 million for the first nine months of 2017, \$24 million for 2016, and \$27 million for 2015. Based on our foreign currency balances of monetary assets and liabilities as of June 1, 2017, we estimate that a 10% adverse change in exchange rates versus the U.S. dollar would result in losses of approximately \$396 million. Although we hedge our primary exposures to changes in currency exchange rates from our monetary assets and liabilities by hedging our primary currency exposures with currency forward contracts, the effectiveness of these hedges is dependent upon our ability to accurately forecast our monetary assets and liabilities. In addition, a significant portion of our manufacturing costs are denominated in foreign currencies. Exchange rates for some of these currencies against the U.S. dollar, particularly the yen, have been volatile in recent periods. If these currencies strengthen against the U.S. dollar, our manufacturing costs could significantly increase. In the event that exchange rates for the U.S. dollar adversely change against our foreign currency exposures, our results of operations or financial condition may be adversely affected. In addition, in connection with the Inotera Acquisition, our exposure to changes in foreign currency exchange rates could increase if not offset by corresponding hedges.

**We may make future acquisitions and/or alliances, which involve numerous risks.**

Acquisitions and the formation or operation of alliances, such as joint ventures and other partnering arrangements, involve numerous risks including the following:

- integrating the operations, technologies, and products of acquired or newly formed entities into our operations;
- increasing capital expenditures to upgrade and maintain facilities;
- increased debt levels;
- the assumption of unknown or underestimated liabilities;
- the use of cash to finance a transaction, which may reduce the availability of cash to fund working capital, capital expenditures, R&D expenditures, and other business activities;
- diverting management's attention from daily operations;
- managing larger or more complex operations and facilities and employees in separate and diverse geographic areas;
- hiring and retaining key employees;
- requirements imposed by governmental authorities in connection with the regulatory review of a transaction, which may include, among other things, divestitures or restrictions on the conduct of our business or the acquired business;



- inability to realize synergies or other expected benefits;
- failure to maintain customer, vendor, and other relationships;
- inadequacy or ineffectiveness of an acquired company's internal financial controls, disclosure controls and procedures, and/or environmental, health and safety, anti-corruption, human resource, or other policies or practices; and
- impairment of acquired intangible assets and goodwill as a result of changing business conditions, technological advancements, or worse-than-expected performance of the acquired business.

In previous years, supply of memory products has significantly exceeded customer demand, resulting in significant declines in average selling prices for DRAM, NAND, and NOR products. Resulting operating losses have led to the deterioration in the financial condition of a number of industry participants, including the liquidation of Qimonda and the 2012 bankruptcy filing by Elpida (now known as MMJ). These types of proceedings often lead to court-directed processes involving the sale of related businesses or assets. We believe the global memory industry is experiencing a period of consolidation as a result of these market conditions and other factors, and we engage from time to time in discussions regarding potential acquisitions and similar opportunities arising out of these industry conditions. To the extent we are successful in completing any such transactions, we could be subject to some or all of the risks described above, including the risks pertaining to funding, assumption of liabilities, integration challenges, and increases in debt that may accompany such transactions. Acquisitions of, or alliances with, high-technology companies are inherently risky and may not be successful and may materially adversely affect our business, results of operations, or financial condition.

**Breaches of our security systems could expose us to losses.**

We maintain a system of controls over the physical security of our facilities. We also manage and store various proprietary information and sensitive or confidential data relating to our operations. In addition, we process, store, and transmit large amounts of data relating to our customers and employees, including sensitive personal information. Unauthorized persons or employees may gain access to our facilities or network systems to steal trade secrets or other proprietary information, compromise confidential information, create system disruptions, or cause shutdowns. These parties may also be able to develop and deploy viruses, worms, and other malicious software programs that disrupt our operations and create security vulnerabilities. Breaches of our physical security and attacks on our network systems could result in significant losses and damage our reputation with customers and suppliers and could expose us to litigation if the confidential information of our customers, suppliers, or employees is compromised.

**Compliance with regulations regarding the use of conflict minerals could limit the supply and increase the cost of certain metals used in manufacturing our products.**

Increased focus on environmental protection and social responsibility initiatives led to the passage of Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act") and its implementing Securities and Exchange Commission regulations. The Dodd-Frank Act imposes supply chain diligence and disclosure requirements for certain manufacturers of products containing specific minerals that may originate in or near the Democratic Republic of the Congo (the "DRC") and finance or benefit local armed groups. These "conflict minerals" are commonly found in materials used in the manufacture of semiconductors. The implementation of these new regulations may limit the sourcing and availability of some of these materials. This in turn may affect our ability to obtain materials necessary for the manufacture of our products in sufficient quantities and may affect related material pricing. Some of our customers may elect to disqualify us as a supplier or reduce purchases from us if we are unable to verify that our products are DRC conflict free.

**We are subject to a variety of laws and regulations that may result in additional costs and liabilities.**

The manufacturing of our products requires the use of facilities, equipment, and materials that are subject to a broad array of laws and regulations in numerous jurisdictions in which we operate. Additionally, we are subject to a variety of other laws and regulations relative to the construction, maintenance, and operations of our facilities. Any of these laws or regulations could cause us to incur additional direct costs, as well as increased indirect costs related to our relationships with our customers and suppliers, and otherwise harm our operations and financial condition. Any failure to comply with these laws or regulations could adversely impact our reputation and our financial results. Additionally, we partner with other companies in our joint ventures, which are also subject to a broad array of laws and regulations. Our ownership in these joint ventures may also expose us to risks associated with their respective compliance with these laws and regulations. Our failure, or the failure of our joint ventures, to comply with these laws and regulations could result in:

- suspension of production;
- remediation costs;
- alteration of our manufacturing processes;

- regulatory penalties, fines, and legal liabilities; and
- reputational challenges.

**We may incur additional tax expense or become subject to additional tax exposure.**

We operate in a number of locations outside the U.S., including Singapore, where we have tax incentive arrangements that are conditional, in part, upon meeting certain business operations and employment thresholds. Our domestic and international taxes are dependent upon the distribution of our earnings among these different jurisdictions. Our provision for income taxes and cash tax liabilities in the future could be adversely affected by numerous factors, including challenges by tax authorities to our tax structure and intercompany transfer pricing agreements, income before taxes being lower than anticipated in countries with lower statutory tax rates and higher than anticipated in countries with higher statutory tax rates, changes in the valuation of deferred tax assets and liabilities, failure to meet performance obligations with respect to tax incentive agreements, and changes in tax laws and regulations. We file income tax returns with the U.S. federal government, various U.S. states, and various other jurisdictions throughout the world. Our U.S. federal and state tax returns remain open to examination for 2012 through 2016. In addition, tax returns that remain open to examination in Japan range from the years 2011 to 2016 and in Singapore and Taiwan from 2012 to 2016. The results of audits and examinations of previously filed tax returns and continuing assessments of our tax exposures may have an adverse effect on our provision for income taxes and cash tax liability.

**We may not utilize all of our net deferred tax assets.**

We have substantial deferred tax assets, which include, among others, net operating loss and credit carryforwards. As of September 1, 2016, our U.S. federal and state net operating loss carryforwards, including uncertain tax benefits, were \$3.90 billion and \$1.94 billion, respectively, which, if not utilized, will expire at various dates from 2017 through 2036. As of September 1, 2016, our foreign net operating loss carryforwards were \$6.04 billion, including \$4.28 billion pertaining to Japan, which will, if not utilized, substantially all expire at various dates from 2019 through 2025. In addition, as a result of the Inotera Acquisition, we added foreign net operating loss carryforwards in Taiwan of \$654 million, which expire on various dates through 2022. As of September 1, 2016, we had valuation allowances of \$1.16 billion and \$765 million against our net deferred tax assets in the U.S. and Japan, respectively.

**A change in ownership may limit our ability to utilize our net operating loss carryforwards.**

If we experience a 50% or greater change in ownership involving shareholders owning 5% or more of our stock, it could adversely impact our ability to utilize our existing net operating loss and credit carryforwards. The inability to utilize existing net operating loss and credit carryforwards would significantly increase the amount of our annual cash taxes reducing the overall amount of cash available to be used in other areas of the business.

On January 18, 2017, our shareholders approved a Section 382 Rights Agreement (the "Rights Agreement"), under which our shareholders of record as of the close of business on August 1, 2016 received one right for each share of common stock outstanding, which entitles certain shareholders to purchase additional shares of our common stock at a significant discount in the event of an ownership change, as defined by Section 382 of the Internal Revenue Code of 1986, as amended. In general, an ownership change will occur when the percentage of our ownership by one or more 5% shareholders has increased by more than 50% at any time during the prior three years. Pursuant to the Rights Agreement, if a shareholder (or group) acquires beneficial ownership of 4.99% or more of the outstanding shares of our common stock without prior approval of our Board of Directors or without meeting certain customary exceptions, the rights would become exercisable. The Rights Agreement is intended to avoid an adverse ownership change, thereby preserving our current ability to utilize certain net operating loss and credit carryforwards; however, there is no assurance that the Rights Agreement will prevent all transfers that could result in such an ownership change.

**The limited availability of raw materials, supplies, or capital equipment could materially adversely affect our business, results of operations, or financial condition.**

Our operations require raw materials and in certain cases, third party services, that meet exacting standards. We generally have multiple sources of supply for our raw materials and services. However, only a limited number of suppliers are capable of delivering certain raw materials and services that meet our standards. In some cases, materials, components, or services are provided by a single supplier. Various factors could reduce the availability of raw materials or components such as silicon wafers, controllers, photomasks, chemicals, gases, photoresist, lead frames, and molding compound. Shortages may occur from time to time in the future. We and/or our suppliers could be affected by laws and regulations enacted in response to concerns regarding climate change, which could increase the cost and limit the supply of our raw materials. In addition, disruptions in transportation lines could delay our receipt of raw materials. Lead times for the supply of raw materials have been extended in the past. If our supply of raw materials or services is disrupted or our lead times extended, our business, results of operations, or financial condition could be materially adversely affected.

Our operations are dependent on our ability to procure advanced semiconductor manufacturing equipment that enables the transition to lower cost manufacturing processes. For certain key types of equipment, including photolithography tools, we are sometimes dependent on a single supplier. From time to time we have experienced difficulties in obtaining some equipment on a timely basis due to the supplier's limited capacity. Our inability to obtain this equipment timely could adversely affect our ability to transition to next generation manufacturing processes and reduce costs. Delays in obtaining equipment could also impede our ability to ramp production at new facilities and increase our overall costs of the ramp. If we are unable to obtain advanced semiconductor manufacturing equipment in a timely manner, our business, results of operations, or financial condition could be materially adversely affected.

**A downturn in the worldwide economy may harm our business.**

Downturns in the worldwide economy have harmed our business in the past and future downturns could also adversely affect our business. Adverse economic conditions affect demand for devices that incorporate our products, such as personal computers, mobile devices, SSDs, and servers. Reduced demand for these products could result in significant decreases in our average selling prices and product sales. A deterioration of current conditions in worldwide credit markets could limit our ability to obtain external financing to fund our operations and capital expenditures. In addition, we may experience losses on our holdings of cash and investments due to failures of financial institutions and other parties. Difficult economic conditions may also result in a higher rate of loss on our accounts receivables due to credit defaults. As a result, our business, results of operations, or financial condition could be materially adversely affected.

**Our results of operations could be affected by natural disasters and other events in the locations in which we or our customers or suppliers operate.**

We have manufacturing and other operations in locations subject to natural occurrences such as severe weather and geological events including earthquakes or tsunamis that could disrupt operations. In addition, our suppliers and customers also have operations in such locations. A natural disaster, fire, explosion, or other event that results in a prolonged disruption to our operations, or the operations of our customers or suppliers, may materially adversely affect our business, results of operations, or financial condition.

**We face risks associated with our international sales and operations that could materially adversely affect our business, results of operations, or financial condition.**

Sales to customers outside the United States approximated 84% of our consolidated net sales for 2016. In addition, a substantial portion of our manufacturing operations are located outside the United States. In particular, a significant portion of our manufacturing operations are concentrated in Singapore, Taiwan, and Japan. Our international sales and operations are subject to a variety of risks, including:

- export and import duties, changes to import and export regulations, customs regulations and processes, and restrictions on the transfer of funds;
- compliance with U.S. and international laws involving international operations, including the Foreign Corrupt Practices Act, export and import laws, and similar rules and regulations;
- theft of intellectual property;
- political and economic instability;
- problems with the transportation or delivery of our products;

- issues arising from cultural or language differences and labor unrest;
- longer payment cycles and greater difficulty in collecting accounts receivable;
- compliance with trade, technical standards, and other laws in a variety of jurisdictions;
- contractual and regulatory limitations on our ability to maintain flexibility with our staffing levels;
- disruptions to our manufacturing operations as a result of actions imposed by foreign governments;
- changes in economic policies of foreign governments; and
- difficulties in staffing and managing international operations.

These factors may materially adversely affect our business, results of operations, or financial condition.

#### **We are subject to counterparty default risks.**

We have numerous arrangements with financial institutions that subject us to counterparty default risks, including cash deposits, investments, capped-call contracts on our stock, and derivative instruments. As a result, we are subject to the risk that the counterparty to one or more of these arrangements will default on its performance obligations. A counterparty may not comply with their contractual commitments which could then lead to their defaulting on their obligations with little or no notice to us, which could limit our ability to take action to mitigate our exposure. Additionally, our ability to mitigate our exposures may be constrained by the terms of our contractual arrangements or because market conditions prevent us from taking effective action. If one of our counterparties becomes insolvent or files for bankruptcy, our ability to recover any losses suffered as a result of that counterparty's default may be limited by the liquidity of the counterparty or the applicable laws governing the bankruptcy proceeding. In the event of such default, we could incur significant losses, which could adversely impact our business, results of operations, or financial condition.

## **ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS**

Our Board of Directors has authorized the discretionary repurchase of up to \$1.25 billion of our outstanding common stock, which may be made in open-market purchases, block trades, privately-negotiated transactions, or derivative transactions. Through the third quarter of 2017, we had repurchased a total of 49 million shares for \$956 million through open-market transactions pursuant to such authorization. Repurchases are subject to market conditions and our ongoing determination of the best use of available cash.

Period		(a) Total number of shares purchased	(b) Average price paid per share	(c) Total number of shares (or units) purchased as part of publicly announced plans or programs	(d) Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs
March 3, 2017	– April 6, 2017	—	\$ —	—	\$ 294,184,917
April 7, 2017	– May 4, 2017	—	—	—	294,184,917
May 5, 2017	– June 1, 2017	—	—	—	294,184,917
		—	—	—	

Shares of common stock withheld as payment of withholding taxes and exercise prices in connection with the vesting or exercise of equity awards are also treated as common stock repurchases. Those withheld shares of common stock are not considered common stock repurchases under an authorized common stock repurchase plan and accordingly are excluded from the above table.

## ITEM 6. EXHIBITS

The following documents are filed as part of this report:

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
3.1	Restated Certificate of Incorporation of the Registrant (1)
3.2	Bylaws of the Registrant, Amended and Restated (2)
10.67	Executive Agreement dated April 26, 2017 by and between Micron Technology, Inc. and Sanjay Mehrotra
10.68	Second Amendment to the Credit Agreement, dated April 26, 2017, by and among Micron Technology, Inc., as borrower, Morgan Stanley Senior Funding, Inc. as administrative agent and collateral agent, and the other agents party thereto and each financial institution party from time to time thereto
31.1	Rule 13a-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a) Certification of Chief Financial Officer
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

(1) Incorporated by reference to Current Report on Form 8-K dated January 26, 2015.

(2) Incorporated by reference to Current Report on Form 8-K dated February 1, 2016.

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Micron Technology, Inc.

---

(Registrant)

Date: June 30, 2017

/s/ Ernest E. Maddock

---

Ernest E. Maddock

Senior Vice President and Chief Financial Officer  
(Principal Financial and Accounting Officer)

## EXECUTIVE AGREEMENT

This Executive Agreement (the “**Agreement**”) is made and entered into by and between Micron Technology, Inc., a Delaware corporation (the “**Company**”), and Sanjay Mehrotra, an individual and Officer of the Company, (the “**Officer**”).

WHEREAS, the Board of Directors of the Company (the “**Board**”) and the Officer recognize that it is in the best interest of the Company to provide for a smooth transition when there is a change in management, and wish to recognize the valued contributions of the Officer; and

WHEREAS, the Company desires to provide the Officer with benefits in consideration for his or her execution of this Agreement, the Release (as defined below) and the instrument titled the Executive Covenant Agreement;

NOW THEREFORE, the parties agree as follows:

1(a). **TERMINATION OF THE OFFICER.** The Company or the Officer may at any time terminate the Officer’s active employment with the Company for any reason, voluntary or involuntary, with or without Cause, by providing notice to that effect in writing. Subject to the Officer signing and not revoking the release required in Section 7, upon the Officer’s “**Qualifying Termination of Employment**”, the Officer shall be entitled to the compensation and benefits described in Section 5(a). Except as provided in Section 5(a), upon the Officer’s Separation from Service, the Officer shall only be entitled to (i) those payments and benefits required by law, (ii) unpaid base salary, (iii) reimbursement of unreimbursed business expenses and (iv) such employee benefits (including equity compensation and paid time off), if any, to which the Officer may be entitled under the Company’s employee benefit plans (“**Accrued Amounts**”). To the extent there is any conflict between the terms and benefits provided under any bonus or incentive program of the Company and this Agreement, the terms of this Agreement shall prevail. The Accrued Amounts shall be paid in accordance with the applicable plan or reimbursement policy, provided that the Officer’s final pay check will be paid as soon as administratively practicable following the Officer’s Separation from Service.

1(b). **QUALIFYING TERMINATION OF EMPLOYMENT.** For purposes of this Agreement, Officer experiences a Qualifying Termination of Employment if the Officer’s employment is terminated (i) by the Company for a reason other than for Cause, (ii) by the Officer for Good Reason, or (iii) as a result of the death or Disability of the Officer. For purposes of this Agreement, “**Cause**”, “**Good Reason**” and “**Disability**” shall have the meaning set forth on Exhibit 1(b), attached hereto and incorporated herein by this reference.

2. **LOSS OF OFFICER STATUS.** Upon receipt by the Officer of a notice of termination from the Company, or at any other time upon the Company’s request, the Officer shall resign immediately as an officer and/or director of the Company.

3. **SEPARATION FROM SERVICE.** The date of the Officer’s “**Separation from Service**” shall be the earliest of: (i) the date of the Officer’s death; or (ii) the date after which the Company and the Officer reasonably anticipate that the level of bona fide services the Officer will perform, whether as an employee or consultant, will permanently decrease to 20 percent or less of the average level of bona fide services performed (whether as an employee or contractor) over the immediately preceding 36-month period (or the full period of services to the Company if the Officer provided services to the Company for less than 36 months).

4. **TRANSITION PERIOD.** For purposes of this agreement, the “**Transition Period**” shall be a one year period immediately following the date of the Officer’s Separation from Service due to a Qualifying Termination of Employment.

5(a). **COMPENSATION DURING THE TRANSITION PERIOD.** Upon the Officer’s Qualifying Termination of Employment, and provided the Officer complies with the terms of this Agreement (including the requirements of Section 7) and the terms of the Executive Covenant Agreement, the Officer, or the Officer’s estate in the event of the Officer’s death, will receive during the Transition Period compensation and cash in lieu of employee benefits as provided on Exhibit 5(a), attached hereto and incorporated herein by this reference.

5(b). **EXECUTIVE BONUS AFTER LOSS OF OFFICER STATUS.** An Officer who ceases to be an Officer but does not cease to be an employee of the Company, and who has not yet incurred a Separation from Service (referred to herein as a “**Non-Officer Employee**”), shall receive, in lieu of an executive bonus pursuant to Section 5(a)(ii)(A) of Exhibit 5(a), a pro-rated executive bonus, if at all, subject to the following terms and conditions:

If as of the date of the Officer's loss of officer status the Non-Officer Employee was a designated participant for an executive bonus plan performance period but the Board or a committee thereof has not yet taken action on any required goal achievement certification for such performance period, the Non-Officer Employee will be entitled to receive his or her executive bonus in the amount so certified, at the same time and in the same manner as the continuing officers of the Company receive payment of their executive bonuses for such performance period, if and only if (A) the specified goals are achieved, as certified by the Company's Board or a committee thereof, (B) payment is made for such achievement pursuant to the terms and conditions of the bonus program to the other participating officers, (C) the Non-Officer Employee is an employee of the Company at the time of payment and (D) the Non-Officer Employee complies with the terms of this Agreement and the terms of the Executive Covenant Agreement.

A Non-Officer Employee that receives a bonus pursuant to the terms of this Section 5(b) shall not be entitled to receive an additional bonus pursuant to Section 5(a)(ii)(A) of Exhibit 5(a) during his or her Transition Period. The amount payable under this Section 5(b) shall be payable at the time and form provided in the applicable bonus plan.

5(c). FURTHER CLARIFICATIONS. It is understood that the Officer, during the period of time in which he or she is a Non-Officer Employee and at any time during the Transition Period, is not entitled pursuant to this Agreement to renew his or her participation in any executive bonus program, receive any new grants of stock options or restricted stock or to the accrual of TOP time (however, Non-Officer Employees would participate in the Company's Time Off Plan). It is further understood that the Officer is not entitled to payment of any compensation that is deferred past the Transition Period due to payment criteria of an incentive program, as those criteria existed as of the date of the Officer's Separation from Service. For the avoidance of doubt, the Officer shall not be entitled to any payment which is earned and payable after the Transition Period pursuant to the terms of the applicable plan or program. No action by the Company or the Company's Board may affect the Officer's receipt of the benefits set forth above, other than as provided herein.

6. CONFIDENTIALITY. The reasons for, and circumstances of, an Officer's termination of employment or change in officer status shall be kept confidential and shall not be disclosed; provided that the Company may disclose such information as the Company determines, in its sole discretion, is either required by law to be disclosed or necessary to be disclosed to serve a valid business purpose.

7. RELEASE. No amount shall be payable to the Officer under Section 5(a) until the Officer signs, and does not revoke, a release of claims in favor of the Company, its affiliates and their respective officers and directors in substantially the form attached hereto as Appendix A (the "Release") during the Release Execution Period. For purposes of this Agreement, the "**Release Execution Period**" shall be the 60-day period commencing on the date of the Officer's Separation from Service.

8. ENTIRE AGREEMENT. Except as otherwise specifically provided herein, this Agreement sets forth the entire agreement and understanding between Micron and Officer relating to the subject matter hereof and supersedes all prior understandings and agreements with respect thereto. No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless contained in a writing signed by both of the parties hereto in accordance with Section 11. Any subsequent change or changes in Officer's duties, salary or compensation will not affect the validity or scope of this Agreement. This Agreement is in addition to, and does not supersede or modify in any fashion, the provisions of the Executive Offer Letter, Executive Covenant Agreement, or the provisions of any confidentiality and intellectual property agreement(s) entered into by the parties hereto (collectively, "Additional Agreements") (and all documents and forms referenced therein), all of which are being executed at or about the same time. The obligations contained in the Additional Agreements shall continue independent of the obligations of one another and of this Agreement.

9(a). SECTION 409A COMPLIANCE. This Agreement is intended to comply with Internal Revenue Code ("**Code**") Section 409A and the applicable Treasury Regulations (together, "**Section 409A**") or an exemption thereunder and shall be construed and administered in accordance with Section 409A. Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. For purposes of Section 409A, each installment payment provided under this Agreement shall be treated as a separate payment. Any payments to be made under this Agreement upon a termination of employment shall only be made upon a "separation from service" under Section 409A. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A, and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by the Officer on account of non-compliance with Section 409A. In the event an amount payable under this Agreement is contingent upon the Officer signing a Release during a Release Execution Period and such Release Execution Period begins in one tax year and ends in the next tax year, such amount



shall be paid on the later of (i) the last day of the Release Execution Period, (ii) if applicable, the date specified in Section 9(b), or (iii) the payment date otherwise set forth in this Agreement.

9(b). SPECIFIED EMPLOYEE PAYMENTS; TIMING. Notwithstanding anything in this Agreement to the contrary, if any amount or benefit that would constitute non-exempt “deferred compensation” for purposes Section 409A would otherwise be payable or distributable under this Agreement by reason of the Officer’s Separation from Service during a period in which the Officer is a Specified Employee (as defined below), then, subject to any permissible acceleration of payment by the Company under Treas. Reg. Section 1.409A-3(j)(4)(ii) (domestic relations order), (j)(4)(iii) (conflicts of interest), or (j)(4)(vi) (payment of employment taxes):

(i) if the payment or distribution is payable in a lump sum, the Officer’s right to receive payment or distribution of such non-exempt deferred compensation will be delayed until the earlier of the Officer’s death or the first day of the seventh month following the Officer’s Separation from Service; and

(ii) if the payment or distribution is payable over time, the amount of such non-exempt deferred compensation that would otherwise be payable during the six-month period immediately following the Officer’s Separation from Service will be accumulated and the Officer’s right to receive payment or distribution of such accumulated amount will be delayed until the earlier of the Officer’s death or the first day of the seventh month following the Officer’s Separation from Service, whereupon the accumulated amount will be paid or distributed to the Officer and the normal payment or distribution schedule for any remaining payments or distributions will resume.

For purposes of this Agreement, the term “**Specified Employee**” has the meaning given such term in Section 409A, provided, however, that, as permitted in Treas. Reg. §1.409A-1(i), the Company’s Specified Employees and its application of the six-month delay rule of Code Section 409A(a)(2)(B)(i) shall be determined in accordance with rules adopted by the Compensation Committee of the Board, which shall be applied consistently with respect to all nonqualified deferred compensation arrangements of the Company, including this Agreement.

9(c). SECTION 280G. This section will be construed in accordance with Code Sections 280G and 4999, or any successor provisions thereto, and the guidance issued thereunder (collectively, “**Section 280G**”), and the terms “parachute payment” and “excess parachute payment” as used herein have the meanings ascribed to them under Section 280G.

(i) If it is determined that the aggregate payments and benefits constituting parachute payments which, but for the operation of this provision, would become payable or distributable by the Company to or for the benefit of Officer, pursuant to this Agreement, any other agreement, or any benefit plan (collectively, the “**Total Payments**”), would result in any excess parachute payments becoming subject to the excise tax imposed by Code Section 4999, or any successor provision thereto, or any interest or penalties with respect to such excise tax (such excise tax, together with such interest and penalties, collectively, the “**Excise Tax**”), then the Total Payments shall be reduced to an amount equal to One Dollar (\$1) less than the maximum amount that could be paid to Officer without giving rise to any Excise Tax (the “**Safe Harbor Cap**”); provided, however, that this reduction shall be applied only if the net after-tax benefit to Officer after such reduction would be greater than the net after-tax benefit to Officer without such reduction (notwithstanding the application of the Excise Tax on the unreduced Total Payments). For the avoidance of doubt, Officer shall be responsible for the payment of any Excise Tax arising from the Total Payments and there shall be no tax gross up on any amounts paid under this Agreement.

(ii) Any reduction in Total Payments required by this provision shall be applied in the following order and, to the extent applicable, in accordance with the rules under Section 409A: (i) first, reduction of cash payments and benefits, in reverse order of the date of payment; (ii) second, cancellation of vesting acceleration of equity awards, in reverse order of the date of grant; and (iii) third, reduction of other non-cash payments and benefits, in reverse order of the date the payment or benefit is to be provided. If the same payment or award date applies to more than one payment or benefit within any of the foregoing categories, the reduction will apply to each such payment or benefit on a pro-rata basis. Subject to the foregoing, the Total Payments shall be reduced so that the reduction of compensation to be provided to Officer is otherwise minimized.

(iii) Unless the Company and Officer otherwise agree in writing, all calculations and determinations necessary to effectuate this provision, including without limitation determinations as to whether a reduction in payments or benefits is required and the amount thereof, whether any item of compensation constitutes a parachute payment, the amount, if any, subject to the Excise Tax (including determinations as to whether any

portion of the excess parachute payments constitutes reasonable compensation for services actually rendered, within the meaning of Code Section 280G(b)(4)(B)), and the present value of any parachute payment, shall be made, consistent with Section 280G, by a public accounting firm and/or tax counsel selected by the Company (which may be the Company's independent public accounting firm or outside tax counsel) (the "**Advisors**"). For this purpose, the Advisors may make reasonable assumptions and approximations; may rely on reasonable, good faith interpretations concerning the application of Section 280G; and may rely upon such other tax, legal, valuation or other specialists as they deem appropriate. Officer's applicable federal, state, and local income taxes shall be computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes. The Company and Officer agree to furnish the Advisors with such information and documents as the Advisors reasonably request to make such calculations and determinations as soon as practicable upon such request. The Company shall direct the Advisors to provide Officer with a written statement of its conclusions, setting forth the basis therefor, including detailed supporting calculations and copies of any written opinions or advice upon which such conclusions rely (the "**Report**"), within ten (10) business days after their receipt of all required information and documents. Officer shall have five (5) business days thereafter to notify the Advisors and the Company in writing of any reasonable and substantive objections to the Report. The Company shall direct the Advisors to promptly consider in good faith and respond to such objections, and provide Officer a revised Report reflecting appropriate adjustments (unless the Advisors determine that no adjustments are necessary). The Advisors' final calculations and determinations (as adjusted, if applicable) shall be conclusive and binding on all parties for all purposes. The Company shall bear all costs the Advisors may reasonably incur in connection with the process contemplated by this paragraph.

10. IDAHO OPERATIONS, GOVERNING LAW, AND VENUE. Officer understands and agrees that Micron is headquartered in Idaho and its executive management team is located in Idaho. While Officer will be allowed, for his convenience, to perform work for Micron out of Milpitas, California, Officer will maintain an office at Micron's headquarters in Boise, Idaho and will work out of that office with such regularity as the Board and Officer determine to be necessary for Officer to fulfill my duties as CEO. Officer understands that it is his responsibility to run a company headquartered in Boise, Idaho. In addition, Micron will make residence arrangements in Boise, Idaho for Officer, and Officer will be deemed an Idaho resident for income tax purposes.

Accordingly, this Agreement, for all purposes, shall be construed in accordance with the laws of Idaho without regard to conflicts of law principles. Any action or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located in the state of Idaho. The parties hereby irrevocably submit to the jurisdiction of such courts and waive the defense of inconvenient forum to the maintenance of any such action or proceeding in such venue.

11. MODIFICATION. No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Officer and by an authorized officer of the Company as directed by the Board. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power, or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power, or privilege.

12. CAPTIONS. Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference to the caption or heading of any section or paragraph.

13. SEVERABILITY. Should any provision of this Agreement be held by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this Agreement.

The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language to this Agreement, or by making such other modifications as it deems warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law.

The parties expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event, should one or more of the provisions of this Agreement be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as provided above, this Agreement shall be construed as if such invalid, illegal, or unenforceable provisions had not been set forth herein.

14. REPRESENTATION BY COUNSEL. Officer acknowledges that he has been represented by independent counsel in the negotiation and execution of this Agreement, specifically including but not limited to its choice of law, jurisdiction, and venue provisions.

IN WITNESS WHEREOF, the parties have executed this Agreement, effective as of the date of later signature below.

MICRON TECHNOLOGY, INC.

OFFICER

/s/ April Arnzen  
\_\_\_\_\_  
By: April Arnzen  
Title: Vice President, Human Resources

/s/ Sanjay Mehrotra  
\_\_\_\_\_  
Name: Sanjay Mehrotra  
Title: CEO Micron Technology, Inc.

April 26, 2017  
\_\_\_\_\_  
Date

April 26, 2017  
\_\_\_\_\_  
Date

Exhibit 1(b)  
Special Defined Terms

(i). For purposes of this Agreement, the following terms shall have the meaning set forth below:

“Cause” shall mean any of the following acts by the Officer, as determined by the Board:

- (a) the commission by the Officer of, or the Officer’s pleading guilty or nolo contendere to, a felony or a crime involving moral turpitude (including pleading guilty or nolo contendere to a felony or lesser charge which results from plea bargaining), whether or not such felony, crime or lesser offense is connected with the business of the Company or any of its affiliates;
- (b) the Officer’s engaging in any other act of dishonesty, fraud, intentional misrepresentation, moral turpitude, illegality or harassment, whether or not such act was committed in connection with the business of the Company or any of its affiliates;
- (c) the willful and repeated failure by the Officer to follow the valid and lawful directives of the Board;
- (d) any material violation of the Company’s written policies;
- (e) any intentional misconduct by the Officer in connection with the Company and any of its affiliates’ businesses or relating to the Officer’s duties, or any willful violation of any laws, rules or regulations; or
- (f) the Officer’s material breach of any employment, severance, non-competition, non-solicitation, confidential information, or restrictive covenant agreement, or similar agreement, with the Company or an affiliate.

The determination of the Board as to the existence of “Cause” shall be conclusive on the Officer and the Company.

“Change in Control” means and includes the occurrence of any one of the following events:

- (a) individuals who, as of the effective date of the Agreement (the “**Effective Date**”), constitute the Board of Directors of the Company (the “**Incumbent Directors**”) cease for any reason to constitute at least a majority of such Board, provided that any person becoming a director after the Effective Date and whose election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors then on the Board shall be an Incumbent Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to the election or removal of directors (“**Election Contest**”) or other actual or threatened solicitation of proxies or consents by or on behalf of any Person other than the Board (“**Proxy Contest**”), including by reason of any agreement intended to avoid or settle any Election Contest or Proxy Contest, shall be deemed an Incumbent Director; or
- (b) any person is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934 (the “**1934 Act**”)), directly or indirectly, of either (A) 35% or more of the then-outstanding shares of common stock of the Company (“**Company Common Stock**”) or (B) securities of the Company representing 35% or more of the combined voting power of the Company’s then outstanding securities eligible to vote for the election of directors (the “**Company Voting Securities**”); provided, however, that for purposes of this subsection (b), the following acquisitions shall not constitute a Change in Control: (w) an acquisition directly from the Company, (x) an acquisition by the Company or a Subsidiary of the Company, (y) an acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary of the Company, or (z) an acquisition pursuant to a Non-Qualifying Transaction (as defined in subsection (c) below); or
- (c) the consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company or a Subsidiary (a “**Reorganization**”), or the sale or other disposition of all or substantially all of the Company’s assets (a “**Sale**”) or the acquisition of assets or stock of another corporation (an “**Acquisition**”), unless immediately following such Reorganization, Sale or Acquisition: (A) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the outstanding Company Common Stock and outstanding Company Voting Securities immediately prior to such Reorganization, Sale or Acquisition beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Reorganization, Sale or Acquisition (including, without limitation, a

corporation which as a result of such transaction owns the Company or all or substantially all of the Company's assets or stock either directly or through one or more subsidiaries, the "Surviving Corporation") in substantially the same proportions as their ownership, immediately prior to such Reorganization, Sale or Acquisition, of the outstanding Company Common Stock and the outstanding Company Voting Securities, as the case may be, and (B) no person (other than (x) the Company or any Subsidiary of the Company, (y) the Surviving Corporation or its ultimate parent corporation, or (z) any employee benefit plan or related trust) sponsored or maintained by any of the foregoing is the beneficial owner, directly or indirectly, of 35% or more of the total common stock or 35% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Surviving Corporation, and (C) at least a majority of the members of the board of directors of the Surviving Corporation were Incumbent Directors at the time of the Board's approval of the execution of the initial agreement providing for such Reorganization, Sale or Acquisition (any Reorganization, Sale or Acquisition which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a "**Non-Qualifying Transaction**"); or

(d) approval by the shareholders of the Company of a complete liquidation or dissolution of the Company.

For purposes of the foregoing Change in Control definition, (i) "**Subsidiary**" means any corporation, limited liability company, partnership or other entity of which a majority of the outstanding voting stock or voting power is beneficially owned directly or indirectly by the Company and (ii) "**Person**" means any individual, entity or group, within the meaning of Section 3(a)(9) of the 1934 Act and as used in Section 13(d)(3) or 14(d)(2) of the 1934 Act.

"Compensation for Services" means any form of compensation (including cash, property, or contractual right to future compensation) given or promised in exchange for services provided by the Officer during the Transition Period as an employee, consultant, board member, owner, service partner, advisor or in any other similar capacity, excluding compensation for services to a board previously approved by the Board and excluding earnings the Officer receives for his own personal investing activities in public companies or investments in which he does not actively participate as an employee, consultant, board member, owner, service partner, advisor or in any other similar capacity.

"Disability" means the Separation from Service of the Officer after the applicable authorized party under the long-term disability plan (the "**LTD Plan**") maintained by the Company or its affiliate has provided written notification to the Human Resources Department that the Officer qualifies for disability benefits under the LTD Plan (a "**Disability Notice**"). If the Officer is not eligible for disability benefits under any applicable LTD Plan, then the Officer shall not be able to incur a Disability termination under this Agreement. For purposes of the foregoing, the Officer shall be treated as terminating for Disability under this Agreement only if the Human Resources Department has received a copy of the Disability Notice before processing the Officer's termination.

Notwithstanding the foregoing, for purposes of changing the form of payment from installments to lump sum under Section (i) of Exhibit 5(a), a Change in Control shall not be deemed to have occurred unless such transaction constitutes a change in the ownership of the Company, a change in effective control of the Company, or a change in the ownership of a substantial portion of the Company's assets, each within the meaning of Section 409A.

"Good Reason" shall mean any of the following, without the Officer's consent: (i) a material diminution in Officer's base salary (other than an across-the-board reduction in base salary that affects all peer employees); (ii) a material diminution in Officer's authority, duties, or responsibilities; or Company's failure to nominate the Officer for election to the Board and to use its best efforts to have him elected or re-elected to the Board, as applicable; (iii) the relocation of Officer's principal office to a location that is more than twenty-five (25) miles from the location of Officer's principal office on the effective date of the Agreement; provided, however, that Good Reason shall not include (A) any relocation of Officer's principal office which is proposed or initiated by Officer; (B) a relocation to Boise, Idaho, or (C) any relocation that results in Officer's principal place office being closer to Officer's then-current principal residence, or (iv) a material breach by Company of this Agreement or other written material obligation of the Company to the Officer.

A termination by Officer shall not constitute termination for Good Reason unless Officer shall first have delivered to the Company written notice setting forth with specificity the occurrence deemed to give rise to a right to terminate for Good Reason (which notice must be given no later than ninety (90) days after the initial occurrence of such event) (the "**Good Reason Notice**"), and the Company has not taken action to correct, rescind or otherwise substantially reverse the occurrence supporting termination for Good Reason as identified by Officer within thirty (30) days following its receipt of such Good Reason Notice. Officer's date of termination for Good Reason must occur within a period of three hundred and sixty five (365) days after the initial occurrence of an event of Good Reason.

Exhibit 5(a)  
Compensation During the Transition Period

(i) An amount equal to two times the Officer's annual base salary as of the date of the Officer's Separation from Service paid bi-weekly during the Transition Period in roughly equal installments in accordance with the Company's normal payroll cycle commencing (or in the case of Separation from Service that occurs on, or within one year following, a Change in Control (as defined in Exhibit 1(b)), paid in a single lump sum payment) within 60 days following the Officer's Separation from Service (or such later date as may be required by Section 9 of the Agreement), provided, however:

(A) if the Officer or the Company terminated the Officer's status as an officer of the Company but not as an employee prior to the date of the Officer's Separation from Service, then the base salary payable pursuant to this subsection during the Transition Period shall be the greater of (1) the Officer's base salary in effect immediately prior to the Officer's loss of officer status or (2) the Officer's base salary as of the date of the Officer's Separation from Service;

(B) if as of the date of the Separation from Service the Officer's base salary is subject to a temporary reduction in an effort to save costs, then the base salary payable pursuant to this subsection during the Transition Period shall be the Officer's base salary immediately prior to such reduction.

(C) if the Officer has become entitled to the payment provided under this Section (i) of Exhibit 5(a) solely on account of his Good Reason resignation that does not occur on, or within one year following, a Change in Control, then the amount payable under this Section (i) of Exhibit 5(a) may be forfeited in accordance with Section (vii) of this Exhibit 5(a).

(D) if an installment payment otherwise payable under this Section (i) of Exhibit 5(a) is not paid during the Release Execution Period (and the Officer is otherwise entitled to such payment hereunder), then in a manner consistent with Section 9(b), the first installment that becomes payable to the Officer shall include any installment payments that would have been paid (but were not paid) during the Release Execution Period so that the Officer remains entitled to the full benefit provided under Section (i) of Exhibit 5(a), notwithstanding the suspension of payments that may occur as a result of any suspension of payments during the Release Execution Period.

(ii)(A) A pro-rated executive bonus based on the number of days the Officer was employed during the applicable performance period, payable at the same time and in the same form the bonus will be paid under the applicable plan, subject to the following terms and conditions:

If as of the date of the Officer's Separation from Service, the Officer was a designated participant for an executive bonus plan performance period but the Board or a committee thereof has not yet taken action on any required goal achievement certification for such performance period, the Officer will be entitled to receive his or her executive bonus in the amount so certified, at the same time and in the same manner as the continuing officers of the Company receive payment of their executive bonuses for such performance period, if and only if (A) any required certification thereof by the Board or a committee thereof occurs during the Transition Period, (B) the specified goals are achieved, as certified by the Company's Board or a committee thereof, and (C) payment is made for such achievement pursuant to the terms and conditions of the bonus program to the other participating officers during the Transition Period.

An Officer that receives a bonus, including a pro-rated bonus, pursuant to the terms of Section 5(b) shall not be entitled to receive an additional bonus pursuant to this Section (ii)(A) of Exhibit 5(a).

(ii)(B) An additional executive bonus equal to two times the Officer's target annual bonus under the plan described in Section 5(a)(ii)(A) of this Exhibit 5(a) in effect for the performance period in which his Separation from Service occurred (without regard to achievement of the applicable annual performance objectives), payable in a single lump sum on the last day of the Transition Period (or such later date as may be required by Section 9 of the Agreement).

(iii) Subject to Section (vii) of this Exhibit 5(a), with respect to "time-based" options (including the Offer Options granted to the Officer under his Offer Letter, dated April 26, 2017), and/or "performance-based" options that have not previously become vested, the continued vesting and exercisability of any granted stock options in accordance with the terms of the applicable stock plan as if the Officer's employment as an officer had continued during the Transition Period, provided, however, and for purposes of clarification, the parties agree that the Officer shall be entitled to vesting for the completion of "performance-based" goals hereunder if and only if the specified performance goal was achieved prior to or during the Transition Period and any required goal achievement certification for such performance goal has been made by the Board, or a committee thereof, thereafter;

(iv) Subject to Section (vii) of this Exhibit 5(a), with respect to restricted stock awards, or RSAs, (including the Offer RSAs granted to the Officer under his Offer Letter, dated April 26, 2017) the lapse of any “time-based” and/or “performance-based” restrictions at the same time and in the same amounts such restrictions would have lapsed, if at all, in accordance with the terms of the applicable stock plan if the Officer’s employment as an officer had continued during the Transition Period, provided, however, and for purposes of clarification, the parties agree that the Officer shall be entitled to the lapse of “**performance-based**” restrictions hereunder if and only if the specified performance goal was achieved prior to or during the Transition Period and any required goal achievement certification for such performance goal has been made by the Board, or a committee thereof, thereafter;

(v) Participation and vesting in the Company’s RAM 401(k) Plan (or a successor or replacement plan) (the “**401(k) Plan**”) will cease pursuant to the terms of the 401(k) Plan (generally, the date of the Officer’s termination of employment) and standard termination options under the 401(k) Plan will apply.

If the Officer is contributing to the 401(k) Plan at the date of the Officer’s Separation from Service and has not reached the maximum matching contribution for the 401(k) Plan year(s) covered by the Transition Period, then an amount equal to the difference between the Officer’s actual matching contribution and the amount of matching that the Officer would have received if the Officer had continued to defer his or her income into the 401(k) Plan for the Transition Period and, in addition, for the one year period following the Transition Period at the same rate as was in effect on the date of the Officer’s Separation from Service will be paid to the Officer. The payment, if any, will be calculated as though the Officer were 100% vested in such contribution and will be paid within 60 days after the date of the Officer’s Separation from Service (or such later date as may be required by Section 9 of the Agreement); and

(vi) The Officer’s participation, if applicable, will cease in the Company’s non-cash benefit plans (medical, dental, life, etc.) pursuant to the terms of the applicable plan (generally, the end of the calendar month which includes the date of the Officer’s termination of employment) unless the Officer properly elects to continue participation pursuant to any applicable COBRA continuation or conversion rights. The Officer may also be able to secure individual coverage with similar terms and conditions. It is the Officer’s responsibility to make any timely elections required and for the payment of premiums.

Regardless of the Officer’s election, to the extent the Officer was participating in the Company’s non-cash benefit plans on the date of the Officer’s Separation from Service, the Company will pay the Officer an amount equal to two times the difference in premiums between what the Officer would have paid as an employee during the Transition Period and what the Officer would have to pay during the Transition Period to continue coverage, based on rates in effect at the time of calculation for the region listed by the Company as the Officer’s work address. If COBRA rates are available, those rates will be used in the calculation, followed by any applicable conversion rate, and finally, in the absence of COBRA or conversion rates, by the cost of individual coverage with similar terms and conditions. The payment, if any, will be paid within 60 days after the date of the Officer’s Separation from Service (or such later date as may be required by Section 9 of the Agreement).

Notwithstanding anything herein to the contrary, no compensation will be paid for the loss of any applicable short-term disability coverage.

(vii) Notwithstanding anything contained in Sections (i), (iii) and (iv) of this Exhibit 5(a), if the Officer has become entitled to the benefits under this Exhibit 5(a) solely on account of his Good Reason resignation that does not occur on, or within one year following, a Change in Control, the:

(A) amount remaining payable under Section (i) of Exhibit 5(a) shall be forfeited by the Officer for any remaining period during the Transition Period after the Officer first receives Compensation for Services or after the Officer is first notified by the Company (by certified mail) that it believes he is receiving Compensation for Services and the Officer has not within 10 days of receiving such notice provided written certification to the Company that he has not received Compensation for Services.

(B) Offer Options and Offer’s RSAs that have not become vested as of the date of the Officer’s Separation from Service shall cease to vest, no longer be exercisable, and be forfeited in accordance with the terms of the applicable option award agreement or restricted stock award agreement, as applicable.

Appendix A

Release



---

---

SECOND AMENDMENT TO THE CREDIT AGREEMENT

among

MICRON TECHNOLOGY, INC.,  
as Borrower

and

THE LENDERS PARTY HERETO,

and

MORGAN STANLEY SENIOR FUNDING, INC.,  
as Administrative Agent and as Collateral Agent

Dated as of April 26, 2017

---

---

JPMORGAN CHASE BANK, N.A.,

as Lead Arranger and Bookrunner

## SECOND AMENDMENT

SECOND AMENDMENT, dated as of April 26, 2017 (this "Amendment"), to the CREDIT AGREEMENT, dated as of April 26, 2016 (as amended by the First Amendment, dated as of October 5, 2016 and as may be further amended, restated, supplemented or otherwise modified from time to time heretofore, the "Existing Credit Agreement" and as amended by this Amendment, the "Amended Credit Agreement") among MICRON TECHNOLOGY, INC., a Delaware corporation (the "Company"), MORGAN STANLEY SENIOR FUNDING, INC., as administrative agent and as collateral agent (the "Administrative Agent"), the other agents party thereto and each of the financial institutions from time to time party thereto.

### WITNESSETH:

WHEREAS, the Company has requested that the Existing Credit Agreement be amended in the manner provided for herein; and

WHEREAS, (a) existing Lenders which consent to this Amendment (the "Consenting Lenders") shall have the pricing of all of their Term Loans adjusted on the Second Repricing Date in accordance with this Amendment; (b) existing Lenders which do not consent to this Amendment (the "Non-Consenting Lenders") shall be paid all accrued and unpaid interest on their Term Loans and have their Term Loans assigned to certain Persons (the "New Lenders") on the Second Repricing Date in accordance with Section 2.26 of the Amended Credit Agreement and such New Lenders shall become Lenders under the Amended Credit Agreement and hold a portion of the Term Loans (or, in the case of any existing Lenders, hold a greater portion of the Term Loans), which Term Loans shall accrue interest on and after the Second Repricing Date at the pricing set forth in this Amendment and (c) the consent of the Required Lenders is required pursuant to Section 2.26 of the Existing Credit Agreement to effectuate the assignment contemplated by the preceding clause (b);

NOW, THEREFORE, the parties hereto hereby agree as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Amended Credit Agreement and used herein shall have the meanings given to them in the Amended Credit Agreement.

#### SECTION 2. Amendments.

(a) Section 1.1 of the Existing Credit Agreement is hereby amended by adding the following definitions in proper alphabetical order:

"Second Amendment": means that certain Amendment to this Agreement, dated as of April 26, 2017, by and among the Company, the Administrative Agent and the other parties thereto.

"Second Repricing Date": as defined in the Second Amendment.

(b) Section 1.1 of the Existing Credit Agreement is hereby amended by deleting clauses (i) and (ii) of the definition of "Applicable Margin" contained therein in their entirety and replacing them with the following:

(i) Base Rate Loans, 1.50% and (ii) Eurodollar Loans, 2.50%.

(c) Section 2.13(b) of the Existing Credit Agreement is hereby amended by deleting the term "Repricing Date" in the first sentence thereof and replacing it with the term "Second Repricing Date".

(d) Notwithstanding anything to the contrary in the Existing Credit Agreement and for the avoidance of doubt, all Term Loans held by Non-Consenting Lenders that are assigned pursuant to this Amendment and for which accrued and unpaid interest has been paid pursuant to Section 4(c) shall accrue interest solely on and after the Second Repricing Date. For the further avoidance of doubt, nothing herein shall be deemed to modify the definition of "Applicable Margin" for any day in the relevant Interest Period prior to the Second Repricing Date for purposes of calculating interest accrued prior to the Second Repricing Date.

SECTION 3. Conditions to Effectiveness. This Amendment (other than the amendments to be effectuated pursuant to Section 2 of this Amendment) shall become effective on the date that each of the following conditions shall have been satisfied (or waived by the Required Lenders):

(a) the Administrative Agent shall have received this Amendment, executed and delivered by a duly authorized officer of the Company and acknowledged by the Administrative Agent;

(b) the Administrative Agent shall have received the Consent, substantially in the form of Exhibit A hereto, executed and delivered by duly authorized officers of the Required Lenders and all Consenting Lenders; and

(c) the Administrative Agent shall have received the Acknowledgement and Confirmation, substantially in the form of Exhibit B hereto, executed and delivered by a duly authorized officer of the Company.

SECTION 4. Conditions to Effectiveness of Section 2. Section 2 of this Amendment shall become effective on the date (the “Second Repricing Date”) occurring on or after April 26, 2017 that each of the following conditions shall have been satisfied (or waived by the Required Lenders):

(a) each New Lender has become a party to the Credit Agreement and this Amendment;

(b) the Administrative Agent shall have received from the Company payment of all fees and expenses required to be paid to the Administrative Agent on or before the Second Repricing Date for which written invoices in reasonable detail have been submitted at least two Business Days prior to the Second Repricing Date;

(c) the Administrative Agent shall have received from the Company, for the benefit of the Non-Consenting Lenders, payment of all accrued interest through the Second Repricing Date with respect to the Term Loans held by the Non-Consenting Lenders and being assigned pursuant to this Amendment;

(d) immediately before and after giving effect to Section 2 of this Amendment, each of the representations and warranties made by the Loan Parties and set forth in each Loan Document shall be true and correct in all material respects with the same effect as if made on the Second Repricing Date (unless stated to relate solely to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects as of such earlier date), in each case other than representations and warranties which are subject to a materiality qualifier, in which case such representations and warranties shall be (or shall have been) true and correct; and

(e) no Default or Event of Default shall have occurred and be continuing, or would result from the effectiveness of this Amendment on the Second Repricing Date.

SECTION 5. New Lenders. Each New Lender, the Administrative Agent and each Loan Party acknowledges and agrees that on the Second Repricing Date, upon the execution and delivery of an Assignment and Acceptance by each New Lender, it (i) shall become a “Lender” under, and for all purposes of, the Amended Credit Agreement and the other Loan Documents with a Term Loan in an amount as set forth on its signature page to this Amendment, (ii) shall be subject to and bound by the terms thereof and (iii) shall perform all the obligations of and shall have all rights of a Lender thereunder. Each Non-Consenting Lender which does not execute such Assignment and Acceptance shall be deemed to have executed and delivered such Assignment and Acceptance in accordance with Section 2.26 of the Amended Credit Agreement and shall be required to assign 100% of the outstanding principal amount of the Term Loans held by such Lender to one or more assignees which have agreed to such assignment.

SECTION 6. No Other Amendment or Waivers; Confirmation. Except as expressly provided hereby, all of the terms and provisions of the Existing Credit Agreement and the other Loan Documents are and shall remain in full force and effect. The amendments contained herein shall not be construed as an amendment of any other provision of the Existing Credit Agreement or the other Loan Documents or for any purpose except as expressly set forth herein or a consent to any further or future action on the part of any Loan Party that would require the waiver or consent of the Administrative Agent or the Lenders. This Amendment shall constitute a Loan Document for purposes of the Amended Credit Agreement and from and after the Second Repricing Date, all references to the Credit Agreement in any Loan Document and all references to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Credit Agreement in the Amended Credit Agreement shall, unless expressly provided otherwise, refer to the Amended Credit Agreement.

SECTION 7. APPLICABLE LAW; WAIVER OF JURY TRIAL. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. EACH PARTY HERETO HEREBY AGREES AS SET FORTH IN SECTION 9.16 OF THE EXISTING CREDIT AGREEMENT AS IF SUCH SECTION WERE SET FORTH IN FULL HEREIN.

SECTION 8. Miscellaneous. (a) This Amendment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Amendment by telecopy or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement.

(b) The provisions of this Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby (including permitted assignees of its Term Loans in whole or in part prior to effectiveness hereof).

SECTION 9. Headings. Section headings herein are included herein for convenience of reference only and shall not constitute a part hereof for any other purpose or be given any substantive effect.

*[Signature Pages Follow]*

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their proper and duly authorized officers as of the day and year first above written.

MICRON TECHNOLOGY, INC.

By: /s/ Donald E. Whitt

---

Name: Don Whitt

Title: Vice President, Tax and Treasury

**MORGAN STANLEY SENIOR  
FUNDING, INC., as Administrative Agent**

By: /s/ Lisa Hanson

---

Name: Lisa Hanson

Title: Vice President

**CONSENT TO SECOND AMENDMENT**

CONSENT (this “Consent”) to SECOND AMENDMENT (“Amendment”) to the CREDIT AGREEMENT, dated as of April 26, 2016 (as amended by the First Amendment, dated as of October 5, 2016 and as may be further amended, restated, supplemented or otherwise modified from time to time heretofore) among MICRON TECHNOLOGY, INC., a Delaware corporation, MORGAN STANLEY SENIOR FUNDING, INC., as administrative agent and as collateral agent, the other agents party thereto and each of the financial institutions from time to time party thereto.

Capitalized terms used in this Consent but not defined in this Consent have meanings assigned to such terms in the Amendment.

The undersigned Lender hereby irrevocably and unconditionally approves the Amendment and consents to reprice 100% of the outstanding principal amount of the Term Loans held by such Lender in accordance with the terms of the Amendment.

IN WITNESS WHEREOF, the undersigned has caused this Consent to be executed and delivered by a duly authorized officer as of the date first written above.

\_\_\_\_\_  
as a Lender (type name of the legal entity)

By: \_\_\_\_\_  
Name:  
Title:

If a second signature is necessary:

By: \_\_\_\_\_  
Name:  
Title:

FORM OF ACKNOWLEDGMENT AND CONFIRMATION

1. Reference is made to (i) the Second Amendment, dated as of April 26, 2017 (the "Second Amendment") and (ii) the CREDIT AGREEMENT, dated as of April 26, 2016 (as amended by the First Amendment, dated as of October 5, 2016 and as may be further amended, restated, supplemented or otherwise modified from time to time heretofore, the "Existing Credit Agreement") among MICRON TECHNOLOGY, INC., a Delaware corporation (the "Company"), MORGAN STANLEY SENIOR FUNDING, INC., as administrative agent and as collateral agent (the "Administrative Agent"), the other agents party thereto and each of the financial institutions from time to time party thereto.

2. The Existing Credit Agreement is being amended pursuant to the Second Amendment. The undersigned hereby agrees, with respect to each Loan Document to which it is a party:

(a) all of its obligations, liabilities and indebtedness under such Loan Document shall remain in full force and effect on a continuous basis after giving effect to the Second Amendment; and

(b) all of the Liens and security interests created and arising under such Loan Documents remain in full force and effect on a continuous basis, and the perfected status and priority of each such Lien and security interest continues in full force and effect on a continuous basis, unimpaired, uninterrupted and undischarged, after giving effect to the Second Amendment, as collateral security for its obligations, liabilities and indebtedness under the Existing Credit Agreement and under its guarantees in the Loan Documents.

**3. THIS ACKNOWLEDGMENT AND CONFIRMATION SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.**

4. Delivery of an executed counterpart of a signature page of this Acknowledgment and Confirmation by telecopy or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Acknowledgment and Confirmation.

[rest of page intentionally left blank]



IN WITNESS WHEREOF, the undersigned has caused this Acknowledgement and Confirmation to be duly executed and delivered by its proper and duly authorized officer as of the day and year first above written.

**MICRON TECHNOLOGY, INC.**

By: \_\_\_\_\_  
Name:  
Title:

[Signature Page to Acknowledgement and Consent]

**RULE 13a-14(a) CERTIFICATION OF  
CHIEF EXECUTIVE OFFICER**

I, Sanjay Mehrotra, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Micron Technology, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 30, 2017

/s/ Sanjay Mehrotra

Sanjay Mehrotra

President and Chief Executive Officer

**RULE 13a-14(a) CERTIFICATION OF  
CHIEF FINANCIAL OFFICER**

I, Ernest E. Maddock, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Micron Technology, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 30, 2017

/s/ Ernest E. Maddock

---

Ernest E. Maddock  
Senior Vice President and Chief Financial Officer

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER  
PURSUANT TO 18 U.S.C. 1350**

I, Sanjay Mehrotra, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Micron Technology, Inc. on Form 10-Q for the period ended June 1, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Micron Technology, Inc.

Date: June 30, 2017

/s/ Sanjay Mehrotra

---

Sanjay Mehrotra

President and Chief Executive Officer

**CERTIFICATION OF CHIEF FINANCIAL OFFICER  
PURSUANT TO 18 U.S.C. 1350**

I, Ernest E. Maddock, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Micron Technology, Inc. on Form 10-Q for the period ended June 1, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Micron Technology, Inc.

Date: June 30, 2017

/s/ Ernest E. Maddock

---

Ernest E. Maddock  
Senior Vice President and Chief Financial Officer